

Index

- 11 β -hydroxylase deficiency, 1077
17 α -hydroxylase deficiency, 1077
- 21-hydroxylase deficiency, 1073
forms of, 1075
late-onset, 1073
prenatal diagnosis, 1075
- 3 β -hydroxysteroid
dehydrogenase
deficiency, 1077
- 5 α -reductase deficiencies, 901
- abdominal pain, *see also* pelvic
pain
adolescents, 556
ectopic pregnancy, 256
abdominal pregnancy, 263
abdominal wall
endometriosis symptoms, 208
tenderness test, 57
abnormal uterine bleeding
(AUB), 112,
see also menorrhagia
classification, 112–13
definitions, 112
diagnosis, 112–14
anovulatory bleeding, 114
differential diagnosis, 1008
heavy menstrual bleeding,
113–14
endometrial cancer, 757–8
epidemiology, 112
evaluation, 114–16, 1008–11
leiomyoma manifestations,
229–30
perimenopausal, 1008–13
causes, 1008
treatment, 116–18
acute onset bleeding, 118
anovulatory bleeding, 118
heavy menstrual bleeding,
116–18
intrauterine therapy, 1012
non-hormonal therapies, 1013
oral contraceptives, 1011–2
progestins, 1012, 1014
surgery, 1013
- uterine sarcoma association,
770, 773
- abscess
Bartholin gland, 311
management, 311–12
surgical site infection, 387–8
tubo-ovarian, 350, 352, 356
laparoscopic removal, 614
abstinence syndrome, 69
Abuse Assessment Screen, 96
acanthosis nigricans, 948, 1031
acetowhite epithelium, 169
cervix, 171, 173
vagina, 174
acne, 552
management, 1041
oral contraceptive benefits,
962
acne inverse, 309
acromegaly, 870, 874, 933
acrosome reaction test, 907
ACTH (adrenocorticotrophic
hormone), 1056–8
9 am plasma ACTH
measurement, 1065
ACTH stimulation test, 513,
548, 953, 1071
deficiency, 1069–70
ectopic ACTH syndrome, 1063
associated tumors, 1063
treatment, 1067
activin, 497, 979
acute perihepatitis, 326
acute urethral syndrome, 326
addiction, 69, 832
pseudo-addiction, 832
Addison disease, 1068–9
causes, 1068–9
autoimmune adrenalitis,
1068–9
adenocarcinoma, *see also* cervical
cancer; endometrial
cancer; ovarian cancer;
uterine cancer; vaginal
cancer
cervical, 748–9
endocervical
adenocarcinoma in situ,
160–1
endometrial, 755
ovarian, 790
uterine, 191
vaginal, 737, 741
adenomyosis
imaging, 192
menorrhagia relationship, 114
adenosarcoma, 773,
see also uterine sarcoma
adhesiolysis, 68, 574, 580–4,
611–12
risks and benefits, 572
adhesions, 303, 611–12, 675
Asherman syndrome, 954
chronic pelvic pain
association, 65, 572
fertility impairment, 612, 867
formation, 612
intrauterine, 659
hysteroscopic lysis, 658–9
recurrent pregnancy loss
association, 923
reproductive outcome, 659
labial, children, 544
laparoscopic management,
580–4, 611–12
periovarian, 206
prevention, 303, 657
treatment, 68
adjuvant therapy
breast cancer, 681–2, 684–6
cervical cancer, 751
endometrial cancer, 761–5
ovarian cancer, 797, 801
surgery, 298
IVF adjuncts, 885–6
uterine sarcoma, 776
adnexal masses, 194–6, 616–18,
see also specific masses
children/adolescents, 574–8
differential diagnosis, 584
physical examination, 575
clinical presentation, 617
etiology, 616–17
evaluation, 617
tumor markers, 617
imaging, 575–6, 584
laboratory tests, 576, 584
management, 576–8, 617–18
- adnexal torsion
evaluation, 579
management, 580
pediatric patients, 578–80
adolescents, *see also* pediatric
patients
abdominal pain causes, 556
abnormal cervical cancer
screening results, 160
adnexal masses, 574–8
imaging, 575–6
laboratory tests, 576, 584
management, 576–8
physical examination, 575
colposcopy, 180
congenital anomalies, surgical
correction, 580–4
contraception, 550–6
abstinence, 551–2
barrier methods, 554
choice of, 554–5
compliance enhancement,
554–6
emergency contraception, 553
hormonal methods, 552–3
incorrect use, 554
injectable contraceptive, 553
intrauterine methods, 554
motivating and non-
motivating factors, 556
oral contraceptives, 552–6
progestin-only methods, 553
transdermal patch, 552
vaginal ring, 553
dysmenorrhea, 556–7
endometriosis, 557–8, 572
treatment, 557–8
gynecological examination,
537–40
indications, 549
hirsutism, 546–50
causes, 555
diagnosis, 546–8
treatment, 548–50
pelvic pain, 570–4
causes, 556
PCOS, 1032
adrenal crisis, 1074
treatment, 1070

Index

- adrenal glands,
see also hypoadrenalism
 function, 1056–8
 androgen secretion,
 1059–60
 mineralocorticoid secretion,
 1058–9
 history of study, 1057
 adrenal hyperplasia,
see also congenital
 adrenal hyperplasia
 infertility association, 869–70
 adrenal hypoplasia congenital,
 1069
 adrenal insufficiency,
see also hypoadrenalism
 clinical features, 874
 infertility association, 869–70
 adrenal tumors, 509, 514
 cortisol-secreting, 1063
 detection, 954
 adrenalectomy
 bilateral, 1067
 unilateral, 1067
 adrenarache, 493, 520
 premature, 498
 adrenocorticotrophic
 hormone, *see* ACTH
 adult respiratory distress
 syndrome, 391
 aging
 bone mass changes, 4–6
 sexual dysfunction
 relationships, 75
 skin
 perimenopausal, 988
 urogenital, 44–5
 aging population, 44
 AIDS, 362, *see also* HIV
 adrenal involvement, 1069
 air embolism, 674, 676
 alcohol intake
 leiomyoma risk relationship,
 226
 recurrent pregnancy loss
 relationship, 924
 alcohol misuse, 128–9
 counseling, 128–9
 preconception counseling,
 143
 pseudo-Cushing syndrome
 and, 1064
 screening, 128–9
 aldosterone secretion, 1058–9
 alendronate, 24, 993,
see also bisphosphonates
 allopregnanolone, 28
 alpha-thalassemia, 140
 alprazolam, 40
 ambulatory urodynamics,
 459–60
 amenorrhea, *see* primary
 amenorrhea; secondary
 amenorrhea
 aminoglutethimide, 1067
 amitriptyline
 fecal incontinence
 management, 441
 interstitial cystitis treatment, 67
 anal canal, 433–5
 bulking by injection, 448
 anal incontinence, 405–6,
see also fecal
 incontinence
 diagnosis
 electromyography, 438–9
 history, 436
 anal intraepithelial neoplasia,
see perianal
 intraepithelial neoplasia
 anal manometry, 438
 anal sphincter, 401–2, 433
 injuries, 405–6
 pediatric patients, 566
 anal sphincteroplasty, fecal
 incontinence
 management, 443–5
 anal warts, 345, 377
 analgesics, *see also specific drugs*
 chronic pelvic pain, 68–70
 perioperative pain, 283
 anaphylaxis, antimicrobial
 prophylaxis and, 284
 anastrozole
 breast cancer treatment, 684
 PCOS management, 953
 androgens
 adrenal secretion, 1059–60
 conversion disorders, 901
 excess, 114, 116, *see also* hyper-
 androgenism
 PCOS, 1026–31
 leiomyoma management, 241
 premenstrual syndrome
 pathogenesis, 28
 receptor disorders, 901
 supplementation, 46
 sexual dysfunction
 management, 76, 80–1
 synthesis disorders, 903
 androstenedione, 978, 1026
 anejaculation, 904
 treatment, 914
 anemia, 131
 angiogenic factors,
 endometriosis, 206
 anorexia nervosa, 5, 503, 525, 944
 anorgasmia, *see* orgasmic
 disorder
 anovulation, 868, 982
 hypergonadotropic, 876–7
 hyperprolactinemic, 877
 hypogonadotropic, 877
 normogonadotropic, 876
 PCOS, 1029, 1031
 anovulatory bleeding, 114,
see also abnormal uterine
 bleeding
 evaluation, 116
 treatment, 118
 anticholinergic drugs
 urinary incontinence
 management, 412–13,
 420
 anticoagulants, pregnancy and,
 143
 anticonvulsants
 cancer pain management, 839
 pregnancy and, 142
 antidepressants, *see also specific
 drugs*
 adverse effects, 35
 chronic pelvic pain
 management, 70–1
 sexual dysfunction
 relationships, 76
 antihypertensive drugs,
 pregnancy and, 142
 antimicrobial prophylaxis,
 283–5, 301
 adverse effects, 284
 bowel preparation, 284–5
 endocarditis, 284, 291
 surgical site infection, 385–6
 antimicrobial therapy, *see specific
 conditions*
 anti-Müllerian hormone (AMH),
 887, 979–80
 assessment, 874, 980
 perimenopausal changes, 1007
 PCOS and, 1029
 antinuclear antibodies, 924
 antioxidant therapy, subfertile
 males, 914
 antiphospholipid syndrome, 923
 antiprogesterones, leiomyoma
 management, 240–1
 antiretroviral therapy, 363–4
 HIV transmission prevention,
 365
 anti-sperm antibodies, 907
 antithyroid antibodies, 922
 antral follicle count, 887
 appendicitis, 571
 arcus tendineus fascia pelvis, 401
 arcus tendineus levator ani, 401
 Arias–Stella reaction, 255
 aromatase inhibitors
 breast cancer treatment, 684
 metastatic disease, 686
 leiomyoma management, 241
 male infertility management,
 911
 PCOS management, 953, 1038
 arousal disorder, *see* sexual
 arousal disorder
 arteriovenous malformation, 114
 artificial neosphincter, 446–7
 artificial urinary sphincter, 427
 Asherman syndrome, 659, 954
 hysteroscopic treatment,
 658–9
 Ashkenazi Jewish background,
 140, 680, 698
 aspiration pneumonia, 293
 aspirin, 69, 1000
 assisted hatching, 894
 assisted reproductive technology
 (ART), 875,
see also specific methods
 perimenopausal women,
 1018–9
 asthenospermia, 903
 atelectasis, 293
 atherosclerosis, 1019
 atypical femur fracture, 20–2
 atypical glandular cells, 160–1,
 169
 atypical squamous cells (ASC),
 155, 159, 169
 autoimmune adrenalitis, 1068–9,
 1074
 autoimmune oophoritis, 528
 autoimmune polyendocrine
 syndromes, 1069
 axillary evaluation, 702
 axillary lymph node dissection,
 682
 azoospermia factor
 microdeletions, 902
 back pain, endometriosis, 206
 bacterial vaginosis, *see* vaginal
 infections
 bariatric surgery, 1036–7
 barium enema, 282
 Bartholin gland
 abscess, 311
 management, 311–12
 cancers, 734
 cyst, 311
 management, 311–12
 basal body temperature charts,
 873
 behavior modification,
see also lifestyle
 modification
 urinary incontinence
 management, 410–11
 beta-chorionic gonadotropin,
see human β -chorionic
 gonadotropin
 beta-thalassemia, 140
 Bethesda cervical cytological
 classification, 154, 169
 bevacizumab, ovarian cancer
 treatment, 802–3
 bilateral salpingo-oophorectomy
 endometrial cancer, 761,
 763–4
 endometriosis, 66
 premenstrual syndrome, 39
 prophylactic, 847–8
 uterine leiomyosarcoma,
 775–6
 bimanual pelvic examination,
 209
 biofeedback, fecal incontinence
 management, 441–3
 bioidentical hormones, 990

- bipolar electrocoagulation
endometriosis treatment, 217
- bisphosphonates
cancer pain management, 839
complications, 20–1
drug holiday, 21
osteoporosis management,
18–21, 993
combination therapy, 24
- black cohosh, 90–2
adverse effects, 91
premenstrual syndrome
management, 32
- bladder anesthetic test, 62
- bladder diary, 454–5
information provided, 455
types of, 454
- bladder injuries, 670,
see also cystotomy
during surgery, 302
laparoscopy complications,
668–70
pediatric patients, 565, 567
treatment, 570, 669
- bladder pain, *see* interstitial
cystitis/painful bladder
syndrome
- bladder training, 419
- bleeding disorders, 114
perioperative management,
288
screening, 115
- blood component therapy, 288
- BMD, *see* bone mineral density
- body mass index (BMI), 134, 289
changes at puberty, 502
endometriosis association, 204
leiomyoma risk relationship,
226
- bone age
assessment, 512–13, 525
puberty relationship, 522
workup, 526
- bone mass, 988,
see also osteoporosis
age-related changes, 4–6, 988
assessment, 6, 8
GnRH agonist effects, 240
pregnancy and lactation
effects, 24
- bone metastases, 833
- bone mineral density (BMD), 6,
988, *see also* osteoporosis
assessment, 991
at puberty, 502–3
GnRH agonist effects, 516
hyperprolactinemia effect, 930
indications for testing, 8
least significant change, 11
monitoring, 11
oral contraceptive benefits, 962
protection with secondary
amenorrhea, 949, 955
- bone remodeling, 5–6
- bone turnover markers, 11
- botulinum toxin
A (onabotulinumtoxinA),
urinary incontinence
management, 413
- bowel injuries
laparoscopy complications,
670–1, 675
prevention, 671
pediatric patients, 565
- bowel obstruction, 208
- bowel preparation for surgery,
284–5, 301
- brachytherapy
breast cancer, 683
cervical cancer, 750–1
endometrial cancer, 761–4
vaginal cancer, 741
- brain
changes at puberty, 502
metastases, 826–7
- BRCA genes, 680, 685, 846
breast cancer association, 846
prevention and, 681
screening implications, 699,
707
cancer risk relationship, 697
fallopian tube carcinoma
association, 780
functions of BRCA proteins,
846–7
mutations, 843
implications for carriers,
847–8
ovarian cancer association,
791, 846
prognostic significance, 798
recurrent disease
management, 805
pregnancy and, 855
testing for, 697–8, 847
criteria for testing, 698
- BRCAPRO computer model,
696
- breakthrough pain, 831
- breast
anatomy, 692
blood supply, 692
development, 692–3
embryology, 691–2
health issues, 691
lactation, 693
lymphatic drainage, 692
physiology, 692–3
- breast cancer, 679, 693–4
adjuvant therapy, 681–2,
684–6
axillary lymph node dissection,
682
chemotherapy, 682, 684–6,
855
adverse effects, 686
preoperative, 683
regimens, 685–6
during pregnancy, 855–6
early-stage treatment, 681–6
- epidemiology, 679, 693
mortality, 693
racial variation, 694
- genetics, 845–8
BRCA genes, 846
family history, 845–6
- hormonal treatment, 683–4
- hormone (replacement)
therapy relationships, 46,
996–8
breast cancer survivors, 998
women with benign breast
disease, 997–8
women with positive family
history, 998
- infertility relationships, 878
- metastatic disease treatment,
686–7
chemotherapy, 686–7
HER2/neu-positive disease,
686–7
hormone-receptor positive
disease, 686
- neoadjuvant therapy, 683
- oral contraceptive risks, 963
- PCOS association, 1033
- prevention, 680–1, 695
- radiation therapy, 682
brachytherapy, 683
during pregnancy, 855
following lumpectomy,
682
postmastectomy irradiation,
682–3
side effects, 683
- risk assessment, 695–7, 714–16
ductal lavage, 715
mammary ductoscopy,
715–16
nipple aspirate fluid, 715
random periareolar fine-
needle aspiration, 716
- risk factors, 679–80, 685, 694,
997
family history, 694
screening, *see* breast cancer
screening
sentinel lymph node biopsy,
682
- staging, 681, 686
- surgical treatment, 681–2
breast conservation, 681–3
during pregnancy, 855
invasive cancer, 682
mastectomy, 681
non-invasive cancer, 682
vaccines, 716
- breast cancer screening
BRCA testing, 697–8
criteria for, 698
clinical screening, 698–704
breast self-examination
(BSE), 699–701
clinical breast examination
(CBE), 701–4
- future advances, 716
genetic screening, 847
geriatric population, 45
guidelines, 707
history, 694–5
mammography, 704–9
accuracy, 707
age 40–49, 705–6
age 70 and above, 706
computer-aided detection,
712–13
digital mammography, 708–9
frequency, 706–7
MRI, 710–12
high-risk population,
711–12
positron emission
tomography, 713–14
rates, 699
risk assessment role, 695–7
Sestamibi
scintimammography, 714
ultrasound, 709–10
- breast development, 498, 520
aplasia, 526
delayed puberty diagnosis, 522
premature, 510
evaluation, 512
- Breast Imaging Reporting and
Data System (BI-RADS),
707
- breastfeeding, *see also* lactation
cancer treatment risks, 862
SSRI safety, 36
- Brief Sexual Function Index for
Women (BSFI-W), 82
- bromocriptine
hyperprolactinemia
management, 877, 933–4,
951
PCOS management, 1038
side-effects, 934
- bubo
chancroid, 334
lymphogranuloma venereum,
335
- Burch colposuspension, 424–5
laparoscopic, 629–30
- bupirone, premenstrual
syndrome treatment, 38
- CA125, 617
endometrial cancer evaluation,
758
fallopian tube carcinoma
diagnosis, 783
prognostic significance, 786
ovarian cancer diagnosis, 794
post-treatment surveillance,
803
screening, 792
- cabergoline
hyperprolactinemia
management, 877, 934–5,
951

Index

- cabergoline (cont.)
safety in pregnancy, 935
valvular heart disease
association, 935–6, 938–9
- café-au-lait marks, 511
- calcineurin inhibitors, 270
- calcitonin
osteoporosis management,
993
- calcium intake, 1020
calcium content of foods and
supplements, 17
osteoporosis management,
14–16
premenstrual syndrome
management, 32
recommended intakes by life
stage, 15
- calcium levels, osteoporosis
diagnosis, 14
- cancer genetics, 842–3
breast cancer, 845–8
BRCA genes, 846
family history, 845–6
cancer genes, 843–4, 848
caretaker genes, 843
commonly found mutations,
843
gatekeeper genes, 843
oncogenes, 843–4, 849–50
stability genes, 844
tumor suppressor genes,
844, 850–2
hereditary cancer, 844–5
ovarian cancer, 845–8
BRCA genes, 846
family history, 845–6
- cancer pain
anatomy of, 831
assessment, 833–4
treatment considerations,
834
breakthrough pain, 831
epidemiology, 831
incident pain, 831
management, 830–1, 834–40
anticonvulsants, 839
bisphosphonates, 839
intraplinal analgesia, 835–6
NSAIDs, 839
opioids, 830, 835–9
psychiatric therapy, 835
psychostimulants, 839
rescue medication, 832
steroids, 839
sympathetic ganglionic
blockade, 835
risk factors, 833
bone metastases, 833
neuropathic pain, 833
- candidiasis, 270, 312–14
diagnosis, 313–14
HIV relationship, 367
management, 314–15
risk factors, 314
- carbon dioxide distention
medium, 601
complications, 673
- carbuncles, 309
- carcinosarcoma, uterine, 770,
see also uterine sarcoma
- chemotherapy, 776
surgical treatment, 775
- cardiac complications, 290–2
- cardinal ligaments, 401–2
- cardiovascular disease, 988–9,
lifestyle intervention, 1019–20
PCOS association, 1032–3,
1039
prevention, 993–5, 1039
risk factors, 1014
see also myocardial
infarction;
thromboembolism; stroke
- caretaker genes, 843
- Carnett's test, 57, 208
- Cartesian theory of pain, 570
- caruncle, 46
- cataracts, 988
- CDKN2A, 852
- cellulitis, surgical site, 387
- cephalosporins, antimicrobial
prophylaxis, 284
- cerebrovascular accidents,
see also stroke;
thromboembolism
- cerebrovascular accidents, HT
risk, 46
- cervical biopsy, 159, 170,
see also conization
- during pregnancy, 179
- cervical cancer
carcinoma in situ, 169
classification, 747, 752
diagnosis
frank invasive cancer,
746–8
microinvasive cervical
cancer, 746
during pregnancy, 753, 856
epidemiology, 744
age-specific mortality,
48
geriatric population, 45, 48
etiology, 744–5
HIV association, 160, 366
HPV association, 372, 744–5
genes involved in malignant
transformation, 372
persistent HPV infection,
372, 745
viral genome integration
into host DNA, 372
- imaging, 193–4
metastatic disease, 856
pathogenesis, 372
prognostic factors, 748–9
radiation therapy, 750–1
adjuvant radiotherapy, 751
chemoradiation, 751
- recurrent disease, 752
rehabilitation and supportive
care, 753
screening, *see* cervical cancer
screening
- stage-dependent therapy, 751–2
stage IA1, 751
stage IA2, 751
stage IB1, 751
stage IB2, 751
stage IIA1, 752
stage IIA2, 752
stage IIBb, 752
stage IIIA,B, 752
stage IVA, 752
stage IVB, 752
- staging, 748
lymphadenectomy, 748
surgical treatment, 749–50
exenteration, 750
radical hysterectomy, 749–50
robotic-assisted procedures,
636
- cervical cancer screening,
149–54, 162, 745
abnormal results, 374
adolescents, 160
immunosuppressed women,
160
management of, 154–61
postmenopausal women,
160
pregnant women, 160
controversies, 163–4
discontinuation, 154
frequency, 152–4
geriatric population, 45
initiation, 151–2, 539
new technologies, 163
population coverage, 150
recommendations, 151
- cervical cap, 968
- cervical endometriosis, 209
- cervical factor infertility, 866
diagnosis, 871
treatment, 875
- cervical intraepithelial neoplasia
(CIN), 147–8, 169, 744,
see also squamous
intraepithelial lesions
- diagnosis, 154–61, 752
colposcopy, 168–70
during pregnancy, 856
HIV association, 365–6
treatment, 161–2, 377–8
cryotherapy, 161–2
excisional methods, 161–3
high-grade (HGCIN), 377–8
laser therapy, 161, 163
low-grade (LGCIN), 377
positive endocervical
curettage results and, 378
positive margin results and,
378
- cervical pregnancy, 262–3
- cervical stenosis, 954–5
- cervical warts, 377
- cervicitis, 352
chlamydial, 325–6
clinical presentation, 352
gonococcal, 320
hypertrophic, 326
pelvic inflammatory disease
relationship, 352
- cervix imaging, 190,
see also squamocolumnar
junction; transformation
zone
- cesarean section, urogenital
fistulae and, 465
- chance
chancroid, 334
syphilis, 328, 330
- chancroid, 334–5
clinical features, 334
diagnosis, 334
epidemiology, 334
HIV association, 334
risk factors, 334
treatment, 334–5
- chasteberry, 86
adverse effects, 86
premenstrual syndrome
management, 32, 86
- chemotherapy
breast cancer, 682, 684–6
adverse effects, 686
metastatic disease, 686–7
preoperative, 683
regimens, 685–6
- cervical cancer, 751
during pregnancy, 861
- endometrial cancer, 763–5
recurrence management,
764–5
- fallopian tube carcinoma,
785
- malignant gestational
trophoblastic disease
high-risk disease, 824–6
low-risk disease, 824–6
pregnancy after, 827
salvage chemotherapy, 826
- ovarian cancer, 798–802
advancedstage disease,
799–800
early-stage disease, 798–9,
801
neoadjuvant chemotherapy,
797
recurrent disease, 802–5
uterine sarcoma, 776–7
vaginal cancer, 741
vulvar carcinoma, 733
- chest pain, endometriosis, 207
- childbirth, urinary incontinence
association, 418,
see also obstetric trauma;
perineal trauma during
childbirth

- chlamydia, 323–8,
see also lympho-
 granuloma venereum
Chlamydia spp., 323–4
 clinical features, 325–6
 acute urethral syndrome,
 326
 endocervicitis, 325–6
 endometritis, 326
 pelvic inflammatory disease,
 325–6
 diagnosis, 327
 epidemiology, 323, 325
 gonorrhea coinfection, 322,
 324
 health consequences, 323, 325
 infertility, 254, 867
 perinatal complications, 327
 infection during pregnancy,
 327
 treatment, 328
 risk factors, 325
 screening, 327
 transmission, 324
 to infant, 325
 treatment, 327–8
Chlamydia trachomatis,
see also chlamydia; pelvic
 inflammatory disease
 clinical spectrum, 324
 serotypes, 323
 cholesterol screening, 131
 chorioadenoma destruens,
see invasive mole
 choriocarcinoma, 821
 clinical features, 821
 pathology, 821
 chromosomal abnormalities
 hydatidiform mole, 814–15
 leiomyomas, 227
 male infertility, 902
 recurrent pregnancy loss and,
 921
 risk of, 139
 translocations, 843
 chronic obstructive pulmonary
 disease
 postoperative complications
 and, 292–3
 chronic pelvic pain, 53–65
 adolescents, 570–4
 associated conditions, 54
 adhesions, 65, 572
 chronic pelvic pain
 syndrome, 70
 depression, 65, 571
 endometriosis, 52, 62–3, 572
 interstitial cystitis/painful
 bladder syndrome, 61–2
 irritable bowel syndrome,
 59–61
 pelvic congestion syndrome,
 64
 pelvic inflammatory disease,
 52, 63–4
 challenges and controversies,
 71–2
 clinical features, 53
 complementary therapies, 71
 definition, 51, 570
 criteria, 70, 570
 diagnosis
 diagnostic tests, 61
 laparoscopy, 59
 physical examination,
 57–60, 570
 disease-specific treatment,
 65–8, 573–4
 epidemiology, 51
 pain theories, 570–1
 pathogenesis, 52–3, 570–84
 gastrointestinal causes, 571,
 584
 gynecological causes, 572,
 584
 musculoskeletal causes,
 571–2, 584
 urological causes, 571–2
 pharmacological treatment
 antidepressants, 70–1
 combination therapy, 71
 opioids, 69–70
 peripherally acting
 analgesics, 69
 psychological treatment, 71
 risk factors, 51–2
 age, 51
 obstetrical history, 52
 past surgery, 52
 physical and sexual abuse,
 51, 570
 cigarette smoking, *see* smoking
Cimicifuga racemosa, *see* black
 cohosh
 citalopram, premenstrual
 syndrome treatment, 34
 Claus model of breast cancer
 risk, 696
 clear cell adenocarcinoma of the
 vagina, 737
 management, 741
 clinical breast examination
 (CBE), 701–4
 clitoral repair, 108–9
 clobetasol propionate, lichen
 sclerosus treatment, 277
 clomiphene citrate
 male infertility treatment, 914
 ovarian stimulation for IVF,
 888
 PCOS management, 876, 953,
 1038
 side-effects, 1038
 treatment resistance, 1039
 clomiphene citrate challenge test
 (CCCT), 886–7
 clomipramine, premenstrual
 syndrome treatment, 38
 CMYC, 850
 coelomic metaplasia, 205
 Cohen incision, modified, 299
 cognitive behavioral therapy,
 premenstrual syndrome,
 31
 cognitive changes, menopause,
 987
 HT and, 995–6
 cognitive theories of pain, 570
 cold-knife conization, 161, 169
 colorectal cancer,
see also hereditary non-
 polyposis colorectal
 cancer
 during pregnancy, 860
 HT relationship, 999
 colposcopy, 168–9
 accuracy, 168–70
 adolescents, 180
 assessment systems, 174
 Reid colposcopic index,
 174–5
 Rubin and Barbo system,
 174, 176
 challenges, 181
 findings
 abnormal transformation
 zone, 173–4
 cancer features, 177–8
 high-grade squamous
 intraepithelial lesions, 177
 low-grade squamous
 intraepithelial lesions, 176
 normal transformation
 zone, 173
 immunosuppressed patients,
 180–1
 indications, 170–1
 postmenopausal women, 180
 pregnant women, 178–80
 procedure, 171–4
 adequate colposcopy, 169,
 172
 subsequent management, 181–3
 vaginal, 174
 vulvar, 174
 colposuspension
 Burch procedure, 424–5
 laparoscopic, 425–6
 needle suspension, 426
 combined oral contraceptives,
see oral contraceptives
 communication issues, geriatric
 patients, 45
 complementary and alternative
 medicine, 85,
see also specific therapies
 chronic pelvic pain, 71
 drug interactions, 92
 hot flashes, 989
 leiomyomas, 241
 premenstrual syndrome, 32, 86
 preoperative patients, 92
 complete blood count, pelvic
 inflammatory disease,
 353
 compression stockings, 286
 computed tomography (CT),
 188
 bone mass assessment, 6
 computer-aided detection, breast
 cancer, 712–13
 condoms, 967
 adolescent contraception, 554
 female condoms, 967
 HIV transmission prevention,
 365, 367, 554
 condyloma acuminata, *see* genital
 warts
 congenital adrenal hyperplasia
 (CAH), 509, 903, 1073–7
 11 β -hydroxylase deficiency,
 1077
 17 α -hydroxylase deficiency,
 1077
 21-hydroxylase deficiency,
 1073
 forms of, 1075
 late-onset, 1073
 prenatal diagnosis, 1075
 3 β -hydroxysteroid
 dehydrogenase
 deficiency, 1077
 diagnosis, 513, 874, 948
 features of gene-specific
 defects, 1074
 heterozygote deficiency,
 1073–6
 hirsutism and, 548
 infertility association, 869
 lipoid congenital adrenal
 hyperplasia, 528
 management, 1076–7
 amenorrhea, 953–4
 salt-wasting form, 1073
 simple virilizing form, 1073
 steroidogenic acute regulatory
 protein (StAR) deficiency,
 1077
 congenital anomalies,
see also specific anomalies
 infertility association, 867
 surgical correction in
 adolescents, 580–4
 uterine, 190–1
 recurrent pregnancy loss
 and, 922–3
 congenital bilateral absence of
 the vas deferens, 870,
 904
 conization, 161, 169, 173
 during pregnancy, 179
 indications, 173
 consanguinity, 140
 constipation, 47
 adolescents, 571
 management, 68
 constitutional delay in pubertal
 development, 522, 526,
see also delayed puberty
 contact dermatitis, 272–3

Index

- contraception, 958,
see also specific methods
 adolescents, 550–6
 abstinence, 551–2
 barrier methods, 554
 choice of, 554–5
 compliance enhancement,
 554–6
 emergency contraception, 553
 hormonal methods, 552–3
 incorrect use, 554
 intrauterine contraception,
 554
 motivating and non-
 motivating factors, 556
 progestin-only methods, 553
 barrier methods, 967
 cervical cap, 968
 characteristics of contraceptive
 methods, 969
 condoms, 967
 contraceptive implant, 960
 depot medroxyprogesterone
 acetate, 966–7
 diaphragm, 967–8
 efficacy, 958
 emergency contraception,
 968–70
 HIV-infected patients, 367–8
 hormonal methods, 961
 progestin-only
 contraception, 966
 hydatidiform mole and, 819
 injectable contraceptive, 553
 intrauterine devices (IUD),
 959–60,
*see also levonorgestrel-
 releasing intrauterine
 system*
 copper IUD, 959–60
 long-acting reversible
 contraception, 958–9
 oral contraceptives, 552–6
 perimenopausal women, 1010
 postpartum, 970
 spermicides, 968
 transdermal patch, 552, 964–5
 vaginal ring, 553, 965–6
 Cooper's ligaments, 692
 copper IUD, 959–60
 risks, 959
 corpus luteum, 978, 981
 cysts, 196
 corticosteroids, 1060–1,
see also steroid treatment
 hypothalamic–pituitary
 –adrenal axis
 suppression, 1060–1
 withdrawal, 1060–1
 corticotropin-releasing hormone,
 1056–7
 test for, 1066
 cortisol
 dexamethasone suppression
 tests, 1064–5
 excess, 1061,
see also glucocorticoids
 cortisol-secreting adrenal
 tumors, 1063
 inactivation, 1029
 measurement, 1064
 Cortrosyn, 1060
 coumestans, 87, 990
 COX-2 inhibitors, 283
 cancer pain, 839
 dysmenorrhea, 556–7
 cretinism, 1048
 Crohn disease, rectovaginal
 fistula and, 480, 482, 488
 cryotherapy, cervical
 intraepithelial neoplasia,
 161–2
 cryptorchidism, 902
 CT (computed tomography),
 188
 culdocentesis
 ectopic pregnancy diagnosis,
 258
 pelvic inflammatory disease
 diagnosis, 352, 355–6
 Cushing disease, 1061–3
 Cushing syndrome, 869, 874,
 948, 1061–2
 cause determination, 1065–6
 corticotropin-releasing
 hormone test, 1066
 fasting plasma ACTH
 measurement, 1065
 high-dose dexamethasone
 suppression test, 1065
 imaging studies, 1066
 inferior petrosal sinus
 sampling, 1066
 metyrapone test, 1065
 plasma potassium, 1065
 scintigraphy studies, 1066
 causes of, 1063
 diagnosis, 1064–5
 dexamethasone suppression
 tests, 1064–5
 evaluation, 954
 iatrogenic, 1064
 prognosis, 1068
 pseudo-Cushing syndromes,
 1064
 symptoms, 1063
 treatment, 1067
 adrenal causes, 1067
 ectopic ACTH syndrome,
 1067
 medical treatment, 1067
 pituitary-dependent
 syndrome, 1067
 cyclooxygenase inhibitors,
see COX-2 inhibitors
 cyproterone acetate, 516, 550,
 1040
 cyst, *see also ovarian cysts*
 Bartholin gland, 311
 management, 311–12
 cystadenoma
 mucinous, 198
 serous, 197
 cystectomy, adolescents, 578
 cystic fibrosis, 140, 904
 CFTR (cystic fibrosis
 transmembrane
 conductance regulator)
 mutations, 870, 904
 cystitis, *see interstitial cystitis/
 painful bladder syndrome*
 cystometry, 421, 456–7
 cystoscopy, 62
 cystotomy, 465–6, 628,
see also bladder injuries
 prevention, 468
 repair, 468
 cystourethroscopy, 467
 cytochrome P450 (CYP)
 enzymes, 1027
 cytoreductive surgery, 794–8
 interval debulking, 797
 D&C, *see dilatation and curettage*
 danazol
 endometriosis management,
 66, 215
 leiomyoma management, 241
 premenstrual syndrome
 management, 39
 side-effects, 215, 1012
 danger assessment, 97
 daVinci Robotic Surgical System,
 598
 Davydov neovagina creation
 procedure, 582
 DAX1 mutations, 901
 deep vein thrombosis, 303–4,
*see also thrombo-
 embolism*
 diagnosis, 286–7
 Doppler ultrasound, 287
 MR venography, 287
 venography, 287
 management, 286–7
 low-molecular-weight
 heparins, 287
 unfractionated heparin,
 287
 prophylaxis, 285–6
 low-dose heparin, 286
 low-molecular-weight
 heparins, 286
 mechanical methods, 286
 risk factors, 285
 defecation mechanism, 433
 defibulation, 107–8
 antenatal, 108
 benefits, 104
 intrapartum, 108
 dehydroepiandrosterone
 (DHEA), 1026, 1059
 adrenal androgen replacement
 therapy, 1073
 sexual dysfunction and, 81
 delayed puberty, 521
 clinical features, 525
 differential diagnosis, 522–5
 etiology, 521–2
 laboratory tests, 525–8
 management, 529–31
 hormone therapy, 529–31
 psychological support, 529
 dementia, HT relationship, 995–6
 denosumab, 993
 osteoporosis management, 23
 dependence, 69
 psychological, 69
 depot medroxyprogesterone
 acetate (DMPA), 966–7
 adolescent contraception, 553
 bone density impact, 14
 leiomyoma risk relationship,
 226
 non-contraceptive health
 benefits, 966
 risks, 966
 side-effects, 967
 depression, 130–1,
see also antidepressants
 chronic pelvic pain
 association, 65, 571
 diagnosis, 1018
 perimenopausal, 987, 1016–7
 pseudo-Cushing syndrome
 and, 1064
 risk factors, 131, 1015
 screening, 130–1
 St. John's wort therapy, 85–6
 dermoid cyst, 197
 Derogatis Sexual Function
 Interview, 82
 desvenlafaxine, hot flash
 management, 1015
 dexamethasone
 cancer pain management, 839
 PCOS management, 876, 1038
 dexamethasone suppression
 tests, 954, 1064–5
 dextran 70 distention medium,
 601–2
 complications, 673
 diabetes, 133
 diagnosis, 874
 HT relationship, 996
 infertility association, 869
 management, 133, 1039
 perioperative, 289
 postoperative, 289
 PCOS association, 1032, 1039
 postoperative infection risk
 and, 385
 preconception counseling,
 141–2
 preoperative assessment, 289
 screening, 133
 diabetic ketoacidosis, 289
 diaphragm
 contraceptive, 967–8
 pelvic, 399–402

- diarrhea management, 68
 diet, 126–7
 counseling, 126–7
 preconception counseling, 140–1
 ovarian cancer relationship, 791
 dietary management
 fecal incontinence, 440
 interstitial cystitis, 67
 irritable bowel syndrome, 67
 premenstrual syndrome, 30
 dietary supplements, *see specific supplements*
 differentiated thyroid cancers
 during pregnancy, 858–9
 diffusion-weighted imaging, 189
 digital mammography, 708–9
 dihydrotestosterone (DHT), 1027
 dilatation and curettage (D&C)
 ectopic pregnancy diagnosis, 258
 endometrial cancer diagnosis, 757
 laparoscopic instrumentation, 597
 dimethylsulfoxide, interstitial cystitis treatment, 66–73
Dioscorea villosa, *see wild yam*
 diphenoxylate, fecal incontinence management, 441
 disorders of sexual development, 528, 580
 disseminated gonococcal infection, 321, 323
 disseminated intravascular coagulation, 390
 DMPA, *see depot medroxyprogesterone acetate*
 DNA repair, 847
 dobutamine, 391
 documentation, intimate partner violence, 97
 domestic violence, *see intimate partner violence*
 dong quai, 87
 donor insemination, 894
 donor oocytes, 894–5
 donovanosis, *see granuloma inguinale*
 Doppler ultrasound, deep vein thrombosis, 287
 Down syndrome risk, 139
 drospirenone, premenstrual syndrome management, 38
 drug abuse, 129
 counseling, 129
 dual energy X-ray absorptiometry
 bone mass assessment, 6, 9
 ductal carcinoma in situ (DCIS), 682
 detection, 710–11
 ductal lavage, 715
 duloxetine, premenstrual syndrome management, 38
 dynamic graciloplasty, 445–6
 dyschezia, endometriosis association, 206
 dysmenorrhea, 556
 adolescents, 556–7
 endometriosis and, 206
 following female genital mutilation, 106
 leiomyoma association, 230
 NSAID treatment, 556–7
 oral contraceptive benefits, 962
 presacral neurectomy, 630–1
 dyspareunia, 56, 79
 chronic pelvic pain association, 53
 endometriosis association, 206
 following female genital mutilation, 105
 treatment, 81
 dysplasia, 169
 early menopause, 951
 early puberty, *see puberty*
 ectopic ACTH syndrome, 1063
 associated tumors, 1063
 treatment, 1067
 ectopic pregnancy, 205–6
 diagnosis, 255–60
 algorithm, 260
 culdocentesis, 258
 D&C, 258
 hCG levels, 256–7
 history, 256
 laparoscopy, 258
 physical examination, 256
 serum progesterone measurement, 258
 ultrasonography, 257–8
 epidemiology, 253–4
 laparoscopic treatment, 261, 613–14
 medical treatment, 260–1
 pathogenesis, 255
 risk factors, 254–5
 contraception, 255
 infertility treatment, 255
 pelvic inflammatory disease, 254
 tubal surgery, 254, 613
 rupture, 255–6
 spontaneous resolution, 262
 surgical treatment, 261–2
 surgical approach, 261
 surgical technique, 261–2
 types, 253, 262–5
 abdominal pregnancy, 263
 cervical pregnancy, 262–3
 following hysterectomy, 264
 heterotopic pregnancy, 264
 in a hysterotomy scar, 264
 interligamentous pregnancy, 264
 interstitial pregnancy, 263
 multiple ectopic pregnancies, 264
 ovarian pregnancy, 261, 263
ERBB2 (HER2/neu), 686–7
 efavirenz, 364
 ejaculatory duct obstruction, 904
 transurethral resection, 913
 ejaculatory dysfunction, 904
 treatment, 914
 elderly patients, *see geriatric population*
 electrical stimulation, urinary incontinence management, 419–20
 electroejaculation, 914
 electromyography, fecal incontinence assessment, 438–9
 embryo cryopreservation, 894–5
 embryo donation, 895
 embryo reduction, 893
 embryo transfer, 891, 894
 mock transfer, 891
 embryonic rests, 205
 emergency contraception, 553, 968–70
 endocarditis prophylaxis, 284, 291
 endocervical assessment, 169
 endocervical curettage, 169
 endocervical sampling, 169
 endometrial ablation, 662
 abnormal uterine bleeding management, 117–18, 662
 perimenopausal, 1013
 hysteroscopic, 662
 leiomyoma treatment, 245–6
 pregnancy following, 675–6
 endometrial biopsy
 endometrial cancer detection, 116, 757
 ovulation detection, 873
 pelvic inflammatory disease, 354
 perimenopausal abnormal uterine bleeding, 1009
 uterine sarcoma diagnosis, 773
 endometrial cancer
 anovulation relationship, 114
 chemotherapy, 763–5
 diagnosis, 757–8
 endometrial biopsy, 116
 hysteroscopy, 663
 elderly patients, 48
 epidemiology, 755
 follow-up care, 765
 menopausal symptom management, 765
 hereditary, 848
 histology, 755–6, 759
 HT relationships, 998–9
 imaging, 193
 metastatic disease, 758–61, 763
 management, 761–2
 PCOS association, 1033, 1039–40
 perimenopausal, 1009
 presurgical evaluation, 758
 progesterin therapy, 761
 protection, 1039–40
 oral contraceptives, 961, 1014
 radiation therapy, 761–5
 recurrence management, 764–5
 risk factors, 756–7, 1009
 staging, 758–61
 surgical treatment, 761–4
 lymphadenectomy, 761–2
 survival, 765
 types of, 756, 759
 endometrial hyperplasia, 755–6
 perimenopausal, 1009
 treatment, 758
 endometrial neoplasia risk factors, 1009
 endometrial polyps, 48
 diagnosis, 114–15
 hysteroscopic polypectomy, 116–17, 649–50
 menorrhagia relationship, 113
 endometrial sampling, 169
 endometrial stromal sarcoma, 771–3, *see also uterine sarcoma*
 endometrial thickness, *see endometrium*
 endometrioma
 imaging, 197
 ovarian, 206
 treatment, 219
 endometriosis, 203, 618
 adolescents, 557–8, 572
 treatment, 557–8
 challenges, 220–1
 chronic pelvic pain association, 572
 definition, 203
 diagnosis, 63, 208–14, 872–3
 abdominal examination, 208–9
 differential diagnosis, 215
 imaging, 196, 210, 873
 laboratory tests, 210
 laparoscopy, 210, 873
 pelvic examination, 209–10
 surgical diagnosis, 210–15
 epidemiology, 203
 infertility association, 208, 216, 867–8
 diagnosis, 872–3
 treatment effects, 875–6
 intestinal involvement, 219
 medical treatments, 215–16, 237–41, 557–8
 danazol, 215
 GnRH agonists, 66, 215–16
 infertility management, 216

Index

- endometriosis (cont.)
 pain reduction, 216
 progestins, 215
 pathogenesis, 204–6
 coelomic metaplasia, 205
 ectopic attachment and
 invasion of endometrial
 cells, 205–6
 embryonic rests, 205
 hematogenous and
 lymphatic spread, 205
 retrograde menstruation,
 204–5
 source of ectopic
 endometrial cells, 204
 quantification, 214
 risk factors, 203–4
 age, 204
 body mass index, 204
 genetic factors, 204
 increased menstruation, 204
 lifestyle factors, 204
 race, 204
 sites of pelvic involvement, 207
 staging, 867
 surgical treatments, 65–6,
 216–20
 ablative surgery, 216–17
 endometriosis outside the
 pelvis, 219–20
 hysterectomy, 66, 219
 infertility management, 220
 laparoscopy, 65–6, 217
 pain reduction, 220
 surgical excision, 217–19
 symptoms, 206–8
 abdominal wall pain, 208
 asymptomatic
 endometriosis, 208
 back pain, 206
 bladder symptoms, 207
 bowel symptoms, 207–8
 chest and shoulder pain, 207
 dyschezia, 206
 dysmenorrhea, 206
 dyspareunia, 206
 irregular bleeding, 207
 pelvic pain, 52, 62–3, 206
 symptoms distant from the
 abdominal cavity, 208
 visible lesion progression,
 210–14
 endometritis, 954
 chlamydia association, 326
 postabortion endometritis,
 327
 postpartum endometritis, 327
 pelvic inflammatory disease
 and, 355
 endometrium, 190
 atrophy management, 954
 changes during menstrual
 cycle, 981
 increased estrogen exposure
 mechanisms, 1008
 thickness, 47, 190, 193
 endometrial cancer
 detection, 116
 endopelvic fascia, 401
 endothelial progenitor cells, 205
 enhanced recovery partnership
 program, 304–5
 environmental exposures, 143–4
 ePAQ tool, 454
 epidermal growth factor,
 leiomyoma etiology, 229
 epidermoid cysts, 105
 epididymal obstruction, 904
 epididymal sperm aspiration, 913
 epididymovasostomy, 913
 epidural analgesia, 283
 epigastric vessels, 668
 injury, 668
 management, 669
 erectile dysfunction, 904–5
 EROS clitoral therapy device, 81
 erysipelas, 308
Escherichia coli, vaginal, 383
 escitalopram, premenstrual
 syndrome treatment, 35
 essential menorrhagia, 114
 Essure device, 659–61
 estradiol, *see also* estrogen;
 hormone (replacement)
 therapy
 delayed puberty diagnosis,
 525–6
 delayed puberty management,
 530–1
 transdermal, premenstrual
 syndrome treatment, 39
 estrogen, 943, *see also* hormone
 (replacement) therapy
 cardiovascular protective
 effect, 993–5
 cognitive decline relationship,
 995–6
 deficiency, *see also* menopause;
specific symptoms
 amenorrhea management,
 950–1
 geriatric patients, 45–6
 symptoms, 986
 delayed puberty management,
 530–1
 endometrial cancer
 association, 998
 endometrial hyperplasia
 induction, 755–6
 growth role, 502
 hot flash management, 1015
 leiomyoma etiology, 228–9
 menopausal symptom
 management
 following endometrial
 cancer treatment, 765
 osteoporosis management,
 21–2, 46, 992
 perimenopausal changes, 1007
 precocious puberty and, 510
 pubertal changes, 496
 sexual dysfunction
 management, 80, 990
 thromboembolism association,
 995
 urinary incontinence
 management, 411, 990,
 1015
 vaginal atrophy management,
 990
 ethnic background, 140
 ovarian cancer relationship,
 791
 etidronate, 993
 evening primrose oil, 86–7
 adverse effects, 87
 drug interactions, 87
 premenstrual syndrome
 management, 32
 exemestane
 breast cancer prophylaxis, 680
 breast cancer treatment, 684
 exenteration, 750
 exercise
 counseling, 126
 excess, 949
 health benefits, 126
 osteoporosis management,
 17–18
 premenstrual syndrome
 management, 30
 external pneumatic compression,
 286
 eye disease, perimenopausal, 988
 fallopian tube
 carcinoma, 779
 chemotherapy, 785
 clinical features, 780
 diagnosis, 782–4
 epidemiology, 780
 genetic factors, 780
 hormone therapy, 785
 pathology, 781–2
 prognostic factors, 785–6
 radiation therapy, 784
 risk factors, 780
 spread, 780
 staging, 781
 surgical treatment, 784
 survival, 785
 obstruction, 614
 hysteroscopic treatment,
 661
 patency evaluation, 189, 234,
 870–2
 tubal factor infertility, 867
 diagnosis, 189, 234, 871–2
 treatment, 875
 fallopian tube surgery, 614–16
 ectopic pregnancy risk, 254,
 613
 sterilization, 254, 612–13
 abnormal uterine bleeding
 association, 114
 falls
 prevention, 991
 risk of, 991
 fecal continence mechanism,
 433
 fecal diversion, 448
 fecal incontinence, 405–6, 432
 controversies, 448–9
 diagnosis, 436–9
 manometry, 438
 physical examination, 436–7
 pudendal nerve terminal
 motor latencies, 439
 ultrasonography, 437–8
 epidemiology, 432–3
 non-surgical treatment, 440–1
 biofeedback, 441–3
 medical agents, 441
 obstetric injury association,
 433, 435–6
 pathogenesis, 433–5
 risk factors, 433
 scoring, 432
 surgical treatment, 443–8
 anal canal bulking by
 injection, 448
 anal sphincteroplasty, 443–5
 artificial neosphincter,
 446–7
 dynamic graciloplasty,
 445–6
 fecal diversion, 448
 radiofrequency procedure
 (Secca), 448
 sacral nerve stimulation,
 447–8
 fecundability rate, 866
 female condoms, 967
 female genital mutilation/cutting
 (FGM/C), 102
 average age, 104
 complications, 104–7
 acute complications, 104–5
 anorgasmia, 106
 blood-borne infections, 106
 dyspareunia, 105
 epidermoid cysts, 105
 genital fistulae, 106, 465
 hematocolpos/
 hematometria/
 dysmenorrhea, 106
 infertility, 106
 influencing factors, 105
 keloid formation, 105
 mental health impact, 104,
 106–7
 obstetric outcomes, 106
 pelvic inflammatory disease,
 106
 recurrent urinary tract
 infections, 106
 countries where prevalent,
 104
 future prospects, 110
 history, 102–3

- legal issues, 109–10
 guidance for doctors, 109–10
 management, 107–9
 clitoral repair, 108–9
 defibulation, 104, 107–8
 re-infibulation, 109
 persistence of, 103
 reasons for propagation, 103
 pregnancy issues, 104
 prevalence, 104–5
 Female Sexual Distress Scale, 82
 female sexual dysfunction (FSD)
 challenges, 83
 classification, 77–9
 hypoactive sexual desire disorder, 77–8
 orgasmic disorder, 79
 persistent genital arousal disorder, 79
 sexual arousal disorder, 78–9
 sexual pain disorders, 79
 diagnosis, 79–80
 elderly patients, 47
 epidemiology, 75
 pathogenesis, 75–7
 aging, 75
 medications, 76–7
 menopausal changes, 76
 psychiatric conditions, 76
 surgical procedures, 76
 trauma, 76
 perimenopausal, 990–1, 1015
 research, 82
 risk factors, 75
 treatment, 80–2
 androgen replacement, 76
 arousal disorders, 81
 desire disorders, 80–1
 guidelines, 80
 HT, 76
 orgasm disorders, 81
 sexual pain disorders, 81
 treatment monitoring, 81–2
 Female Sexual Function Index (FSFI), 82
 femur fracture, atypical, 21–2,
see also hip fracture
 fentanyl, 837
 fertility, *see also* infertility
 age relationship, 1018
 hyperthyroidism effect, 1050
 hypothyroidism effect, 1048
 perimenopausal women, 1017–9
 terminology, 865
 fertility treatment, *see* assisted reproductive technology; infertility
 fesoterodine, urinary incontinence management, 413
 fetal reduction, 893
 FHIT mutations, 850, 852
 fibrillin-3 (*FBN3*), 1030
 fibroids, *see* leiomyomas
 fimbrioplasty, 615
 finasteride, 1040
 fistulae, *see* urogenital fistulae
 Fitz-Hugh-Curtis syndrome, 326
 flatus incontinence, 405–6
 fluid replacement during surgery, 304
 fluorescent in situ hybridization analysis, sperm, 908
 fluoxetine, premenstrual syndrome treatment, 33
 flutamide, 1040
 fluvoxamine, premenstrual syndrome treatment, 35
 folic acid supplementation, 141
 follicle-stimulating hormone (FSH), 495–6, 888, 943
 changes at puberty, 496
 decreased ovarian reserve assessment, 922
 deficiency, 527
 follicular stimulation, 887
 inhibin effects, 979
 menstrual cycle regulation, 976
 dominant follicle selection, 978–9
 ovarian effects, 976–8
 ovarian maturation and, 496
 ovarian stimulation for IVF, 888
 perimenopausal changes, 1007
 pharmacological preparation, 888
 PCOS and, 1026
 therapeutic role, 876
 precocious puberty and, 513
 subunit mutation, 878
 secondary amenorrhea and evaluation, 947
 management, 949–50
 follicle, ovarian, 973, 976–8
 dominant follicle, 978–9
 perimenopausal changes, 1006
 follicular cysts, 196
 folliculitis, 308–9
 hot-tub folliculitis, 309
 follistatin, 497, 979, 1030
 forceps delivery
 perineal trauma association, 436
 urinary incontinence association, 418
 fracture, 988,
see also osteoporosis
 Cushing syndrome, 1062
 distal forearm, 4
 femur, atypical, 20–2
 hip, 2–3
 prevention, oral contraceptives, 1014
 risk assessment, 991
 risk factors, 6–10, 988
 vertebral, 3–4, 9–10
 fragile X syndrome, 528
 FRAX (Fracture Risk Assessment) tool, 1, 9, 991
 FSH, *see* follicle-stimulating hormone
 fulvestrant, 686
 furuncles, 309
 gabapentin, 839
 Gail model of breast cancer risk, 680, 685, 696
 galactorrhea, 930, 933
Gardnerella vaginalis, 383
 gate theory of pain, 571
 gatekeeper genes, 843
 genetic history taking, 138
 genistein, 88, 990
 genital herpes, 337–9
 diagnosis, 338
 epidemiology, 337
 in pregnancy, 337
 transmission to neonate, 337–8
 pathogenesis, 337
 treatment, 338–9
 genital injuries, pediatric patients, 563–70
 clinical features, 563–5
 evaluation, 565–7
 prevention, 570
 treatment, 568
 genital warts, 342–5, 373–4,
see also human papillomavirus
 clinical features, 343–4
 diagnosis, 344
 epidemiology, 343
 morphological types, 344
 treatment, 344–5, 376–7
 anal warts, 345, 377
 cervical warts, 377
 external warts, 344–5, 376–7
 surgical excision, 376–7
 vaginal warts, 345, 377
 genitofemoral nerve injury, 628
 geriatric population, 44
 breast cancer screening, 45
 cervical screening, 45
 communication issues, 45
 concomitant conditions, 48
 demographics, 44
 estrogen deficiency, 45–6
 gynecological surgery, 48–9
 complications, 48
 history taking, 45
 injury prevention, 130
 osteoporosis, 46
 physical examination, 45
 sexuality, 47
 urinary tract conditions, 46–7
 urogenital aging, 44–5
 vaginitis, 46
 vulvar conditions, 46
 gestational surrogacy, 895
 gestational trophoblastic disease, 813, 855
 choriocarcinoma, 821
 hydatidiform mole, 813–19
 invasive mole (chorioadenoma destruens), 820–1
 malignant, *see* malignant gestational trophoblastic disease
 placental site trophoblastic tumor, 821–2
 risk factors, 814
 gestrinone, leiomyoma management, 241
 Gibson incision, modified, 299
 ginkgo, 87
 sexual dysfunction management, 87
 global ablative surgery, 608
 glucocorticoids, 1056
 bone loss induction, 11
 deficiency, 1060, 1068–77
 excess, 1061–8
 glucose tolerance test, 1034
 glycine distention medium, 601
 complications, 676
 GnRH, 495
 changes at puberty, 496
 deficiency, 974
 gonadotropin stimulation test, 514, 516
 male, 898
 male infertility treatment, 914
 mutations, 527
 pulsatile release, 942, 974–6
 pulsatile therapy, 877
 secondary amenorrhea management, 950
 GnRH agonists, 889, 975
 add-back therapy, 66, 216, 240
 adverse effects, 244, 516
 bone density impact, 14
 delayed puberty diagnosis, 526
 endometriosis treatment, 66, 215–16
 pain management, 216
 hirsutism management, 548, 1040–1
 hypoestrogenic effects, 239–40
 leiomyoma management, 238–40, 244
 complications, 239
 intraoperative, 239
 postoperative, 239
 preoperative, 238–9
 menorrhagia management, 117
 ovarian stimulation for IVF, 888–90
 ovarian hyperstimulation syndrome prevention, 893

Index

- GnRH agonists (cont.)
 precocious puberty treatment, 515–16
 outcomes, 516
 premenstrual syndrome treatment, 39
- GnRH receptor mutations, 527, 870
- goiter, 1048, 1052–3
 clinical presentation, 1052
 diagnosis, 1052–3
 treatment, 1053
- gonadarche, 493, 496
- gonadectomy, 584
- gonadotoxins, 899
- gonadotropin-releasing hormone, *see* GnRH
- gonadotropins, 943,
see also follicle-stimulating hormone;
 luteinizing hormone
- changes at puberty, 496
- deficiency, 526–7
 acquired, 527
 congenital, 526–7
- GnRH stimulation test, 514, 516
- gonadarche and, 496
- ovarian stimulation for IVF, 888
- perimenopausal changes, 1007
- PCOS and 1026
- secondary amenorrhea management, 949–50
- PCOS and therapeutic role, 953, 1038
- gonorrhoea, 319–23
 chlamydia coinfection, 322, 324
 clinical features, 320–1
 in pregnancy, 320
 diagnosis, 321–2
 disseminated gonococcal infection, 321, 323
 epidemiology, 319
 pathogenesis, 319–20
 perinatal complications, 321
 pharyngeal, 320, 322
 risk factors, 320
 screening, 321–2
 transmission, 320
 treatment, 322–3
 antimicrobial resistance, 322
- granuloma inguinale, 336–7
 clinical features, 336
 diagnosis, 336
 epidemiology, 336
 transmission, 336
 treatment, 336–7
- granulosa cells, 976, 980
- grasping instruments, 594–5
- Graves disease, 1049,
see also hyperthyroidism
- gravidity, leiomyoma risk relationship, 224–5
- group support, premenstrual syndrome, 30
- growth hormone, 502
 Turner syndrome management, 529
- gynecological surgery, 297–301,
see also perioperative complications;
 postoperative complications;
 preoperative management; *specific procedures*
- adjuvant surgery, 298
- approach/incision, 298–300
 choice of, 298–9
 Cohen incision, modified, 299
 Gibson incision, modified, 299–300
 midline incision, 299
 suprapubic transverse incision, 299
 vaginal approach, 299–300
- benefit–risk assessment, 298
- collaborative participatory approach, 304–5
- common risks, 303–4,
see also surgical site infection
- adhesions, 303
- hemorrhage, 303
- malnutrition and fluid balance, 304
- pain, 303
- surgical drains, 304
- thromboembolism, 303–4
- unexpected disease or pregnancy, 301–2
- urinary catheters, 304
- urinary tract, 302–3
- corrective surgery, 298
- curative surgery, 298
- HIV-infected women, 366–7
- obese patients, 304
- palliative surgery, 298
- preparation for, 298–300,
see also preoperative management
- instrument/equipment familiarity, 300
- preoperative assessments, 298
- restorative surgery, 298
- Halstead's principles of surgery, 301
- hamartoma, hypothalamic, 507
- harmonic scalpel, 594
- Hashimoto thyroiditis, 1048
- hCG, *see* human β -chorionic gonadotropin
- hearing loss, 124–5
- heavy menstrual bleeding, 113–14,
see also abnormal uterine bleeding; menorrhagia
- evaluation, 114–15
 treatment, 116–18
- hemangioma, vulvar, pediatric patients, 545
- hematocolpos, following female genital mutilation, 106
- hematoma, vulvar, 563–4
 treatment, 567–8
- hematometra, 674
- hematometra, following female genital mutilation, 106
- hemoglobin A1c (HbA1c) test, 1034
- Hemophilus ducreyi*,
see chancroid
- hemorrhage
 during hysteroscopy, 674
 gynecological surgery risks, 303
- hemorrhagic infarction, 234
- heparin, thromboembolism management, 287
- low-dose heparin, 286
- low-molecular-weight heparins, 286–7
- hepatitis, following female genital mutilation, 106
- HER2/NEU (ERBB2), 686–7
- herbal remedies,
see complementary and alternative medicine;
specific herbs
- hereditary non-polyposis colorectal cancer (HNPCC), 844
- endometrial cancer association, 757
- genetic screening, 848–9
- genetics of, 848
- ovarian cancer association, 791
- hereditary tumor syndromes, 849, *see also* cancer genetics
- herpes simplex virus (HSV),
see also genital herpes
- neonatal infection, 337–8
- screening, 338
- vulvar infection, 271
- heterotopic pregnancy, 264
- hidradenitis suppurativa, 309–10
 causative organisms, 310
 treatment, 310–11
- hip fracture, 2–3
- hirsutism
 adolescents, 546–50
 causes, 555
 Cushing syndrome, 1061
 definition, 546
 diagnosis, 546–8
 treatment, 548–50, 1040–1
 excess adrenal androgen production, 550
 excess ovarian androgen production, 548–9
- hair follicle-directed treatment, 550
- histrelin implant, 515
- HIV, 360
 cervical screening recommendations, 181
 chancroid association, 334
 clinical manifestations in women, 361–2
 co-infection with other STDs, 319
 HPV, 343, 365
 contraception issues, 367–8
 diagnosis, 363
 epidemiology, 362–3
 female genital mutilation association, 106
 gynecological manifestations, 365
 cervical cancer, 160, 366
 cervical cytology abnormalities, 180, 365–6
 cervicovaginal infections, 367
 menstrual disorders, 366
 pelvic inflammatory disease, 367
 perianal intraepithelial neoplasia, 366
 vaginal intraepithelial neoplasia, 366
 vulvar intraepithelial neoplasia, 366
 gynecological surgery and, 366–7
 life cycle, 360–1
 pathogenesis, 361–2
 postexposure prophylaxis, 365
 reproduction options, 368
 screening, 363
 transmission influences, 363
 prevention, 364–5
 treatment, 363–4
- HMGIC protein, 227
- HMGII protein, 227
- Hodgkin disease, during pregnancy, 859–60
- hook effect, 931
- hormone (replacement) therapy (HT), 1020–1,
see also hormone treatment
- adverse effects, 46, 999–1000
- benefits, 999
- breast cancer relationships, 996–8
 breast cancer survivors, 998
 women with benign breast disease, 997–8
 women with positive family history, 998
- cardiovascular disease relationships
 protective effect, 993–5

- stroke, 995
thromboembolism, 995
clinical management, 999–1000
cognitive decline relationship, 995–6
colorectal cancer relationship, 999
diabetes relationship, 996
hot flashes, 45, 1015
leiomyoma risk relationship, 226
options, 1000
osteoporosis, 46, 992
perimenopausal women, recommendations, 1019
secondary amenorrhea, 950–1
sexual dysfunction, 76, 990
thromboembolism association, 995
uterine cancer relationships, 998–9
- hormone treatment, *see also* hormone (replacement) therapy
breast cancer, 683–4
delayed puberty, 529–31
during pregnancy, 861
fallopian tube carcinoma, 785
hyperprolactinemia, 951–2
secondary amenorrhea, 949
fertility management, 949–50
hot flashes, 45, 986–7, 1014–5
differential diagnosis, 1015
GnRH agonist side-effects, 240
management, 989–90, 1015
bioidentical hormones, 990
HT, 45, 1015
oral contraceptives, 1015
phytoestrogens, 88–90, 989–90
household injury prevention, 129–30
elderly, 130
HPV, *see* human papillomavirus
HT, *see* hormone (replacement) therapy
human β -chorionic gonadotropin (hCG), 818
ectopic pregnancy diagnosis, 256–7
fallopian tube carcinoma diagnosis, 784
hCG-producing tumor, 513
hydatidiform mole diagnosis, 816
ovarian hyperstimulation syndrome prevention, 893
phantom hCG, 818–19
human immunodeficiency virus, *see* HIV
human leukocyte antigen (HLA), 924
human papillomavirus (HPV), 169, 343, 371–2, *see also* cervical cancer; genital warts
adolescent infections, 180
cervical cytological abnormalities, 374
high-grade squamous intraepithelial lesions, 177
low-grade squamous intraepithelial lesions, 175–6
clinical course of infection, 147–8, 378
clinical features, 373
diagnosis, 374–5, 745
DNA testing, 163
education need, 379
epidemiology, 343, 371
genes involved in malignant transformation, 372
HIV coinfection, 343, 365
infection site, 372
life cycle, 371–2
genome integration in host DNA, 372
natural history of infection, 148–9, 343, 379
persistent cervical infection, 372, 745
psychosocial issues, 379
risk factors for infection, 343, 745
subclinical papilloma infection, 170
treatment, 375–6
types, 371–2
vaccines, 379–80, 745–6
vaginal cancer association, 737
viral genetics, 343
vulvar carcinoma association, 724
vulvar infection, 270
hydatidiform mole, 813–19, 1050
classification, 814–15
complete hydatidiform mole, 814–15
partial hydatidiform mole, 814–15
clinical features, 815–16
contraception and, 819
diagnosis, 816
epidemiology, 813–14
hCG assay, 818
phantom hCG, 819
natural history, 816–17
postmolar gestational trophoblastic disease, diagnostic criteria, 819, 823
reproductive sequelae, 819
treatment, 817–18
follow-up, 818
hysterectomy, 817
non-neoplastic medical complications, 817
prophylactic chemotherapy, 817–18
repeated uterine curettage, 819
suction curettage, 817
twin gestations, 816–17
hydergine, 935
hydrocortisone, 1072, 1076
chronic replacement therapy, 1072–3
hydrodistention of the bladder, 67
hydrometrocolpos, 529
hydromorphone, 837
hydrosalpinx, 614
IVF outcome relationship, 886
hyperandrogenism, 510, 529
diagnosis, 948
hyperinsulinism relationship, 1025
PCOS, 1027
hypercalciuria idiopathic, 14
hyperemesis gravidum, 1050–1
hyperforin, 85
hypericin, 85
Hypericum perforatum, *see* St. John's wort
hyperinsulinism, 1024, *see also* insulin resistance
hyperandrogenism relationship, 1025
hyperparathyroidism, 23
primary, 14
hyperphenylalanemia, 142
hyperprolactinemia, 525, 527, 868
causes, 930–1
pathologic, 931
pharmacologic, 931
physiologic, 931
clinical features, 930
bone mineral loss, 930
galactorrhea, 930
epidemiology, 929
evaluation, 931–3
male, 899
infertility and, 901
management, 877, 933–9
amenorrhea, 951–2
bromocriptine, 877, 933–4, 951
cabergoline, 877, 934–5, 951
controversies, 938–9
duration of medical therapy, 938
hormone treatment, 951–2
irradiation, 937
medications used, 933
no prolactinoma, pregnancy desired, 937
no prolactinoma, pregnancy not desired, 937
observation, 933
pergolide, 935
prolactinoma present, pregnancy desired, 937–8
prolactinoma present, pregnancy not desired, 937
quinagolide, 935
surgery, 936–7
physiology, 929–30
recurrent pregnancy loss relationship, 922
secondary amenorrhea relationship, 947
symptoms, 930
hypertension, 133–4
Cushing syndrome, 1062
preconception counseling, 142
screening, 133–4
hyperthermia, pregnancy and, 143
hyperthyroidism, 114, 1048–52
clinical presentation, 1049–50
diagnosis, 874, 1050–1
during pregnancy, 1050–2
fetal/neonatal, 1050
hydatidiform mole association, 817
infertility association, 869
management, 1051–2
amenorrhea, 952
subclinical, 132
thyroid crisis, 1050–1
hypoactive sexual desire disorder, 77–8
treatment, 80–1
hypoadrenalism, *see also specific conditions*
causes, 1074
clinical features, 1070–1
primary, 1068–9, 1074
diagnosis, 1071
secondary, 1068–70
treatment, 1071–3
acute adrenal insufficiency, 1070–2
chronic replacement therapy, 1070, 1072–3
hypogastric neurolysis, 835
hypogonadotropic hypogonadism, 526, 870, 901
hypoosmotic swelling test, 907
hypothalamic anovulation, 868, 877
hypothalamic hamartoma, 507
hypothalamic–pituitary–adrenal (HPA) axis, 495
hypothalamic–pituitary–gonadal (HPG) axis, 494–5, 898–900
hypothalamus, 898, 974
hypothyroidism, 901, 1047–9
clinical presentation, 1048
congenital, 1049

Index

- hypothyroidism (cont.)
 diagnosis, 874, 1048
 during pregnancy, 1049
 infertility association, 869
 management, 1049
 amenorrhea, 952
 menorrhagia relationship, 114
 precocious puberty
 association, 510
 recurrent pregnancy loss
 relationship, 922
 risk factors, 1048
 screening, 1049
 newborn, 1049
 secondary amenorrhea
 relationship, 947
 subclinical, 131
 treatment, 117
- Hyskon distention medium, 601–2
 complications, 673
- hysterectomy
 cervical cancer treatment,
 749–50
 cervical intraepithelial
 neoplasia treatment, 162
 comparison of methods, 244
 complications, 244
 ureter injury, 669–70
 urogenital fistulae, 465–6
 cystotomy prevention, 468
 endometrial cancer treatment,
 761, 763–4
 endometrial hyperplasia
 treatment, 758
 endometriosis treatment, 66,
 219
 pain reduction, 220
 hydatidiform mole treatment,
 817
 indications, 621
 laparoscopic, 621–6
 laparoscope-assisted radical
 vaginal hysterectomy, 625
 laparoscopic supracervical
 hysterectomy, 623–5
 laparoscopically assisted
 vaginal hysterectomy,
 244, 621
 robotic-assisted radical
 hysterectomy, 632–9
 total laparoscopic
 hysterectomy, 621–3
 total laparoscopic radical
 hysterectomy, 625–6
 leiomyoma treatment, 244–5
 malignant gestational
 trophoblastic disease
 treatment, 824
 perimenopausal abnormal
 uterine bleeding
 management, 1013
 urinary incontinence
 association, 419
 uterine sarcoma management,
 775–6
- hysterosalpingography (HSG),
 189, 615
 leiomyoma detection, 234, 871
 tubal patency evaluation, 872
- hysteroscopy, 600, 648–9,
see also minimally
 invasive surgery
 complications, 672–6
 distention media-associated,
 673, 676
 entry-associated, 672–3
 pregnancy-associated, 675–6
 procedural and
 postoperative, 673–6
 distention media, 600–2
 carbon dioxide, 601, 673
 complications, 673, 676
 dextran 70, 601–2
 glycine, 601
 lactated Ringer solution, 601
 mannitol, 601
 saline, 601
 sorbitol, 601
 endometrial ablation, 662
 endometrial cancer diagnosis,
 663, 757–8
 endometrial polypectomy,
 116–17, 649–50
 fluid monitoring, 602
 instrumentation, 599–600
 flexible hysteroscopes,
 599–600
 instrument availability, 602
 morcellating hysteroscopes,
 600, 654
 resectoscopes, 600
 rigid hysteroscopes, 600
 intrauterine adhesion lysis,
 658–9
 reproductive outcome, 659
 leiomyoma detection, 236–7
 myomectomy, 117, 650–6
 bipolar technique, 653–4
 intrauterine morcellation,
 654
 limitations, 655
 patient positioning, 607
 perimenopausal abnormal
 uterine bleeding
 evaluation, 1009–10
 postmenopausal bleeding
 evaluation, 663
 proximal tubal obstruction
 treatment, 661
 sterilization, 659–61
 surgical setup, 607–8
 diagnostic hysteroscopy,
 607–8
 operative hysteroscopy, 608
 uterine septum treatment,
 655–8
 reproductive outcome,
 657–8
 hysterosonography, leiomyoma
 detection, 235–6
- idiopathic hypercalciuria, 14
 iliococcygeus muscle, 400
 iliopsoas syndrome, 209
 imiquimod, 270
 genital wart treatment, 376
 immune response
 endometriosis pathogenesis,
 205
 septic shock etiology, 389–91
 immunizations, *see* vaccinations
 immunosuppressed patients,
see also HIV
 abnormal cervical cancer
 screening results, 160
 colposcopy, 180–1
 impotence, 904–5
 informed decision making, 305
 in vitro fertilization (IVF), 875,
 884
 assisted hatching, 894
 case history, 895
 complications, 891–3
 infant and childhood
 morbidity, 893
 multifetal pregnancy, 893
 ovarian hyperstimulation
 syndrome, 891–3
 embryo selection, 894
 embryo transfer, 891, 894
 laboratory techniques, 893–5
 complex reproductive
 solutions, 894–5
 luteal support, 891
 oocyte retrieval, 890–1
 outcomes
 age impact, 885
 hydrosalpinx impact, 886
 leiomyoma impact, 232,
 885–6
 patient selection, 884
 PCOS patients, 953
 preparation
 laboratory evaluation, 886–7
 male evaluation, 887
 uterine evaluation, 885
 quality control, 894
 stimulation protocols, 887–90
 follicular stimulation, 887
 GnRH agonists, 888–90
 gonadotropins, 888
 natural cycle, 887–8
 surgical adjuvants, 885–6
 incident pain, 831
 incidentalomas, 948
 incomplete cross-tolerance, 833
 incontinence, *see* fecal
 incontinence; urinary
 incontinence
 infections, 393, *see also* specific
 infections
 adrenal insufficiency and, 1069
 Cushing syndrome, 1062
 development of, 307
 hysteroscopy complications,
 674
- soft tissues, 308
 inferior epigastric injury, 668
 management, 669
 inferior petrosal sinus sampling,
 1066
 infertility, 865, *see also* fertility
 adhesions and, 612, 867
 age-related, 868–9, 1018
 evaluation, 873–4
 management, 877
 cancer relationships, 878
 causes, 866
 cervical factor, 866
 diagnosis, 871
 treatment, 875
 definition, 870, 898
 diagnostic evaluation, 871
 endocrine disorders and,
 869–70
 assessment, 874
 treatment, 877
 endometriosis-associated, 208,
 867–8
 diagnosis, 872–3
 medical treatments, 216
 treatment effects, 875–6
 epidemiology, 865–6
 following female genital
 mutilation, 106
 genetics of, 870
 leiomyoma risk relationship,
 225–6
 leiomyoma-associated, 231–3,
 866–7, 871
 pathological mechanisms,
 233
 male factor, *see* male factor
 infertility
 ovarian factor, 868
 diagnosis, 873
 treatment, 876–7
 PCOS and, 1031
 medical treatment, 1037–9
 obesity control, 1035–7
 surgical treatment, 1039
 prognosis, 877–8
 treatment challenges and
 controversies, 878
 tubal factor, 867
 diagnosis, 871–2
 treatment, 875
 unexplained, 870
 diagnosis, 874
 treatment, 877
 uterine factor, 866–7
 diagnosis, 871
 treatment, 875
 infibulation, *see* female genital
 mutilation/cutting
 inflammation
 endometriosis pathogenesis,
 205–6
 septic shock etiology, 389–91
 infliximab, hidradenitis
 treatment, 310

- informed consent, 282, 284, 297–300
essential components of, 301
presenting risk information, 301
- inguinal endometriosis, 208
- inhibin, 497, 979
perimenopausal changes, 1007
- injury prevention, 129–30
counseling, 129
elderly, 130
- insulin receptor, 1025
INSR, 1030
- insulin resistance, 922, 948
evaluation, 322
management, 1024
insulin sensitizer therapy, 952
PCOS, 1024–5
- insulin-sensitizing agents, 1037–8
hirsutism management, 1041
- insulin-like growth factor (IGF), 980
- interligamentous pregnancy, 264
- International Consultation on Incontinence Modular Questionnaire (ICI), 453
- interstitial cystitis/painful bladder syndrome, 61–2
endometriosis association, 207
treatment, 66–7, 574
- interstitial pregnancy, 263
- intimate partner violence (IPV)
associated health conditions, 95
clinical features, 95–6
diagnosis, 96
screening questions, 96
during pregnancy, 94, 143
outcomes, 95–6
epidemiology, 94–5
homicide risk factors, 99
management, 96–9
organizations/resources, 97
- intracytoplasmic sperm injection (ICSI), 893–4
- intraspinal analgesia, 835–6
- intra-urethral devices, 414
- intrauterine devices (IUD), 959,
see also levonorgestrel-releasing intrauterine system (LNG-IUS)
adolescent contraception, 554
copper IUD, 959–60
- intravenous immunoglobulin, 924
- intravenous pyelography, 282
- invasive mole (chorioadenoma destruens)
clinical features, 821
pathology, 821
treatment, 821
- iodine deficiency, 1048
- irritable bowel syndrome, 59–61
endometriosis association, 207–8
treatment, 67–8, 574
- abdominal pain, gas and bloating, 67
constipation-predominant disease, 67–8
diarrhea-predominant disease, 68
- isoflavones, 87, 89, 990
- isolated menstruation, 506
- isotretinoin, 310, 1041
- IVF, *see* in vitro fertilization
- KAL* mutations, 870
- Kallmann syndrome, 527
male infertility and, 901
- Kartagener syndrome, 903
- karyotype abnormalities,
see chromosomal abnormalities
- Kelly–Kennedy plication, 423
- keloid formation, 105
- ketoconazole, 1067
- ketorolac, 283
- King's Health Questionnaire (KHQ), 453
- kisspeptin, 497, 507
- Klebsiella granulomatis*,
see granuloma inguinale
- Klinefelter syndrome, 902
- knot pusher, 596
- koilocytosis, 148, 169
- KRAS* oncogenes, 849
- labial adhesions, pediatric patients, 544
- lactated Ringer solution, 601
- lactation, 693
bone mass changes, 24
ovarian cancer protection, 791
- Lactobacillus*, vaginal, 350, 382–3
- lactotroph heterogeneity, 930
- laparoendoscopic single site surgery, 596–7
- laparoscopic lymphadenectomy, 626–9
benefits, 627
complications, 627–9
abdominal wall metastases, 628
genitourinary injury, 628
lymphocele formation, 629
neurological injury, 628
requiring laparotomy, 628
vascular injury, 627–8
node retrieval adequacy, 628
surgical technique, 626–7
vulvar cancer, 629
- laparoscopic supracervical hysterectomy, 623–5
- laparoscopically assisted vaginal hysterectomy, 244, 621
aborted procedures, 621
definition, 621
indications, 621
risks and benefits, 621
- ureter injury, 669–70
laparoscopy, 611,
see also minimally invasive surgery
adhesiolysis, 611–12
adnexal mass management, 617–18
children/adolescents, 576–8
colposuspension, 425–6
complications, 666–72
bladder injury, 668–70
bowel injury, 670–1, 675
entry techniques, 667–8
inferior epigastric injury, 668
rates, 666–7
ureter injury, 669–70
vaginal cuff complications, 671–2
vascular injury, 671, 676
- cystectomy, 578
- ectopic pregnancy, 261, 613–14
diagnosis, 258
- endometrial cancer treatment, 761
- endometriosis
diagnosis, 210, 873
treatment, 65–6, 217
- fallopian tube surgery, 614–16
- hysterectomy, 621–6
laparoscope-assisted radical vaginal hysterectomy, 625
laparoscopic supracervical hysterectomy, 623–5
laparoscopically assisted vaginal hysterectomy, 244, 621
robotic-assisted radical hysterectomy, 632–9
total laparoscopic hysterectomy, 621–3
total laparoscopic radical hysterectomy, 625–6
- indications, 611
- instrumentation, 589–99
aspiration needle, 593
bipolar and unipolar systems, 593–4
camera, 589
D&C set, 597
disposable instruments, 597–8
grasping instruments, 594–5
hand assistance, 597
high-flow insufflators, 591
instrument layout, 606–7
laparoscope, 591–2
laparoscopic single site surgery, 596–7
lasers, 594
light source, 591
monitor, 589–91
morcellator, 596
plasma energy, 594
pouches, 596
- scissors, 595
suction-irrigation, 593
suturing instruments, 595–6
trocars, 592–3
ultrasonic scalpel, 594
Veress needle, 592
- lymphadenectomy,
see laparoscopic lymphadenectomy
- Müllerian anomaly correction, 580–1
- myolysis, 245
- myomectomy, 618–21
controversies and challenges, 620
laparoscopically assisted myomectomy, 619
- near-contact laparoscopy, 210
- neovagina creation, 582–3
- ovarian drilling, 1039
- patient positioning, 605–7
- pelvic pain evaluation, 59, 72
- pelvic reconstruction
procedures, 629–30
robotics, 598–9
simulation and virtual reality, 599
- single-port laparoscopy, 631
- sterilization, 612–13
- surgical setup, 604–7
- uterosacral nerve ablation, 66, 630
- laparotomy, ectopic pregnancy treatment, 261
- lapatinib, 686
- laser therapy
cervical intraepithelial neoplasia, 161–3
endometriosis, 217
instrumentation, 594
- Laurence–Moon–Biedl syndrome, 526
- leiomyomas, 223, 618
alternative therapies, 241
classification, 651
clinical manifestations, 229–34, 618
abnormal uterine bleeding, 113, 229–30
infertility, 231–3, 866–7, 871
pelvic pain and pressure, 230–1
pregnancy outcomes, 232–4, 238
recurrent pregnancy loss, 923
- controversies, 246
diagnosis, 114–15, 234–7, 619, 871
hysterosalpingography, 234
hysteroscopy, 236–7
MRI, 191, 236
ultrasound, 191, 234–6
embolization therapy, 241–3
epidemiology, 223–4, 618
genetic etiology, 227

Index

- leiomyomas (cont.)
 heritability, 227–8
 hormonal etiology, 228–9
 estrogen, 228–9
 growth factors, 229
 progesterone, 229
 IVF outcome and, 232, 885–6
 medical treatments, 237–41
 androgens, 241
 antiprogesterones, 240–1
 aromatase inhibitors, 241
 GnRH agonists, 238–40, 244
 LNG-IUS, 117, 237–8
 NSAIDs, 238
 oral and injectable
 contraceptives, 237
 risk factors, 224–7
 age, 223
 gravidity and parity, 224–5
 hormone exposure, 226
 infertility, 225–6
 menstrual factors, 224–5
 race, 223–4
 surgical treatment, 243–6
 abdominal myomectomy,
 245
 hysterectomy, 244–5
 hysteroscopic myomectomy,
 117
 laparoscopic myolysis, 245
 laparoscopic myomectomy,
 618–21
 laparoscopically assisted
 myomectomy (LAM), 619
 leiomyosarcoma, 237, 770–1,
see also uterine sarcoma
 chemotherapy, 776–7
 clinical presentation, 771
 histopathology, 771
 treatment, 775–6
 vaginal, 737, 742
 leptin, 497, 949
 deficiency, 1025
 letrozole, PCOS management, 953
 letrozole, 876, 1038
 leukoplakia, 169, 173
 leuprolide
 hirsutism management, 1040
 precocious puberty treatment,
 515
 levator ani muscle, 399–401
 injury, 403–4
 spasms, 572
 levonorgestrel emergency
 contraception, 968
 levonorgestrel-releasing
 intrauterine system
 (LNG-IUS), 960
 endometriosis treatment, 215
 leiomyoma management,
 237–8
 menorrhagia management,
 117, 960
 versus endometrial ablation,
 662
 perimenopausal abnormal
 uterine bleeding
 management, 1012
 LH, *see* luteinizing hormone
 lichen planus, 268, 277–8
 treatment, 278
 lichen sclerosus, 275–7
 elderly patients, 46
 management, 46
 pediatric patients, 542–3
 treatment, 276–7
 vulvar carcinoma association,
 277, 723
 lichen simplex chronicus, 273–5
 lifestyle modification,
*see also specific lifestyle
 factors*
 interstitial cystitis
 management, 67
 osteoporosis management, 14,
 991
 perimenopausal women,
 1019–20
 premenstrual syndrome
 management, 30
 skin cancer prevention, 125–6
 urinary incontinence
 management, 410–11
 Li-Fraumeni syndrome, 844
 Ligasure, 593
 ligature, 596
 lignans, 87, 990
 lipid disorders, 131–2
 management, 132
 screening, 131–2
 lipid profile
 oral contraceptive benefits, 1014
 PCOS and, 1032
 lipopolysaccharide (endotoxin),
 390
 liver failure, 901
 liver metastases, 827
 LNG-IUS, *see* levonorgestrel-
 releasing intrauterine
 system
 long-acting reversible
 contraception, 958–9
 loop electrosurgical excision
 procedure, 169, 182
 cervical intraepithelial
 neoplasia, 161–3
 loperamide, 68
 fecal incontinence
 management, 441
 loss of heterozygosity, 850
 low-molecular-weight heparins
 (LMWHs), 286–7
 lubiprostone, 68
 Lugol solution, 169, 171–2
 lung metastases, 827
 luteal phase deficiency, recurrent
 pregnancy loss, 921–2
 luteinizing hormone (LH),
 495–6, 943
 changes at puberty, 496
 delayed puberty diagnosis, 526
 LH surge, 943, 980
 diabetes effect, 869
 ovulation prediction, 873,
 952
 premature surges, 889
 male, 899
 menstrual cycle regulation, 976
 dominant follicle selection,
 978–9
 ovarian effects, 976–8
 ovarian maturation and, 496
 perimenopausal changes, 1007
 PCOS and, 1026, 1029
 precocious puberty and, 513
 secondary amenorrhea
 management, 949–50
 subunit gene mutations, 878
 lymphadenectomy,
see also laparoscopic
 lymphadenectomy
 axillary, 682
 cervical cancer, 748
 endometrial cancer, 761–4
 fallopian tube carcinoma, 784
 vulvar carcinoma, 729–31
 lymphocele formation,
 laparoscopic
 lymphadenectomy, 629
 lymphogranuloma venereum
 (LGV), 335–6
 clinical features, 335
 anogenitoretal syndrome,
 335
 inguinal syndrome, 335
 diagnosis, 335–6
 epidemiology, 335
 treatment, 336
 lymphoma, vaginal, 737
 management, 742
 Lynch syndrome, 791, 848
 endometrial cancer
 association, 757
 macroadenoma, 932, 947,
see also hyper-
 prolactinemia;
 prolactinoma
 macroprolactinemia, 931
 macular degeneration, 988
 magnesium supplementation,
 premenstrual syndrome
 management, 32
 magnetic resonance imaging,
see (MRI)
 magnetic resonance venography,
 287
 male factor infertility, 870, 898
 diagnosis, 874–5, 905–10
 genetic analysis, 908
 history, 905–6
 hormone assays, 908
 physical examination, 906
 semen analysis, 874, 887,
 906–8
 testis biopsy, 908–10
 ultrasound, 908
 vasography, 908
 etiology, 898
 acquired disorders, 903
 androgen disorders, 901,
 903
 congenital disorders, 900–1
 ejaculatory dysfunction, 904
 endocrinopathies, 898–901
 erectile dysfunction, 904–5
 exogenous steroids and
 drugs, 901
 genetics, 900, 902–3
 gonadotoxins, 899, 903
 multiorgan syndromes, 903
 neoplasms, 901
 obstruction, 903–4
 post-testicular causes, 900
 sperm motility, 903
 systemic disease, 901
 testicular causes, 900–2
 evaluation before IVF, 887
 health concerns, 903
 treatment, 877, 910–14
 algorithms, 914
 ejaculatory disorders, 914
 endocrinopathies, 911
 genetic disorders, 912
 idiopathic infertility, 914
 varicoceles, 911–12
 vasal obstruction, 912–14
 malignant gestational
 trophoblastic disease, 822
 chemotherapy, 824–6
 pregnancy after, 827
 salvage chemotherapy, 826
 clinical features, 822–3
 diagnosis, 822
 high-risk disease, 825–7
 low-risk disease, 824–6
 metastatic site management,
 826–7
 staging and classification,
 823–6
 surgical treatment, 824
 malonyldialdehyde, 1030
 mammary ductoscopy, 715–16
 mammary glands, *see also* breast
 embryology, 691
 mammography, 699, 704–9,
see also breast cancer
 screening
 accuracy, 707
 age 40–49, 705–6
 age 70 and above, 706
 computer-aided detection,
 712–13
 digital mammography, 708–9
 efficacy evaluation, 704–5
 false-negatives, 707
 frequency, 706–7
 geriatric population, 45
 mannitol distention medium,
 601

- Marshall–Marchetti–Krantz (MMK) surgical procedure, 424
- mastectomy, 681
postmastectomy irradiation, 682–3
prophylactic, 681
- maternal age, 139
- maternal obesity, 1026
- mature cystic teratoma, 197
- Mayer–Rokitansky–Kuster–Hauser (MRKH) syndrome, 190, 529, 582, 870
- Maylard incision, 299
- McCune–Albright syndrome, 509, 1063
treatment, 517
- McGill Pain Questionnaire Short Form, 56–7
- medroxyprogesterone
abnormal uterine bleeding management, 118
adolescent contraception, 553
endometrial cancer management, 764
endometriosis treatment, 215, 557
leiomyoma risk relationship, 226, 237
PCOS management, 952
see also contraception; depot medroxyprogesterone acetate; progestins
- megestrol, *see also* progestins
endometrial cancer management, 761, 764–5
- melanoma
during pregnancy, 859
prevention, 126
vaginal, 737, 742
vulvar, 46, 733–4
- melatonin, 976
- menarche, 494, 498
delayed, 521
premature, 506, 510–11
- menopausal symptoms,
see also specific symptoms
cardiovascular disease, 988–9
cognitive changes, 987
eye diseases, 988
hot flashes (flushes), 986–7
management, 999–1000
black cohosh, 90–1
following endometrial cancer treatment, 765
phytoestrogens, 88–90, 989–90
wild yam, 90
mood changes, 987
osteoporosis, 988
sexual dysfunction, 990–1
skin aging, 988
sleep disturbance, 987
urogenital atrophy, 988
- menopause, 973,
see also menopausal symptoms
age of, 1006
clinical features, 986–9
cultural differences, 986
definition, 1005
diagnosis, 986
early, 951
HIV-infected women, 366
physiological changes, 986
sexual function relationships, 76
- menorrhagia, 113–14
evaluation, 114–15
leiomyoma association, 229–30
oral contraceptive benefits, 962
perioperative management, 288
treatment, 116–18, 960
acute onset bleeding, 118
endometrial ablation, 662
- menstrual cycle, 942–4
endometrium changes, 981
follicular phase, 943
GnRH pulsatile release, 974–6
hyperthyroidism effects, 1050
hypothalamic function, 974
hypothyroidism effects, 1048
luteal phase, 943, 981
deficiency, 982–3
ovarian hormonal changes, 976–8
dominant follicle selection, 978–9
ovulation, 980
perimenopausal irregularity, 1008
pituitary function, 976
variations, 981–3
- Mesterlone, 914
- metabolic syndrome, 1033
- metformin, 289, 516
hirsutism management, 1041
PCOS management, 548–9, 876, 953, 1037–8
pregnancy and, 922
side-effects, 1037
- methicillin-resistant *Staphylococcus aureus* (MRSA), 308
folliculitis, 308
- methimazole, 1051
- methotrexate
ectopic pregnancy treatment, 260–1
follow-up, 261
treatment initiation, 261
side-effects, 260
- methylphenidate, 839
- metyrapone, 1067
test, 1065
- microadenoma, 932, 947,
see also hyperprolactinemia; prolactinoma
- microsatellite instability, 848
- microsurgical epididymal sperm aspiration, 913
- midline incision, 299
- mindfulness meditation, chronic pelvic pain management, 71
- mineralocorticoids, 1056
secretion, 1058–9
- minimally invasive surgery, 604,
see also hysteroscopy; laparoscopy
set-up
equipment, 605
global ablative surgery, 608
instrument layout, 606–7, 609
operating table, 605, 607
patient positioning, 605–7
personnel, 604–5, 607, 609
robotic surgery, 608–9
- miscarriage, 918,
see also recurrent pregnancy loss
age relationship, 869
leiomyoma association, 233
- mismatch repair gene mutations, 757, 791, 845, 848
- mitotane, 1067
- MMK (Marshall–Marchetti–Krantz) surgical procedure, 424
- molar pregnancy,
see hydatidiform mole
- molimina, 28
- molluscum contagiosum, 342
clinical features, 342
diagnosis, 342
treatment, 342
- monopolar electrocoagulation,
endometriosis treatment, 217
- Monsel's solution, 169
- mood changes, menopause, 987
- morcellators, 596
morcellating hysteroscopes, 600
- morphine, 836–7
- mosaic pattern, 169, 174
- motor vehicle accidents, 130
seat-belt counseling, 130
- MRI, 188–9
breast cancer screening, 710–12
high-risk population, 711–12
cervical cancer staging, 748
diffusion-weighted imaging, 189
leiomyoma detection, 236
- mucinous cystadenoma, 198
- mucopurulent cervicitis,
see cervicitis
- Müllerian duct anomalies, 190–1, 580
genetics, 870
laparoscopic correction, 580–1
- multiple organ dysfunction syndrome, 390
- multiple pregnancies
complications, 893
infant and childhood morbidity, 893
ectopic, 264
IVF complications, 893
reduction, 893
- MYC genes, 844
- myocardial infarction
oral contraceptive risks, 963
perioperative, 290–2
- myofascial pain, 572
- myomas, *see* leiomyomas
- myomectomy, 245
before IVF, 885–6
hysteroscopic, 600, 650–6
bipolar technique, 653–4
intrauterine morcellation, 654
limitations, 655
impact on fertility, 232, 245
indications, 619
laparoscopic, 618–21
controversies and challenges, 620
laparoscopically assisted, 619
recurrence rates, 245
- nafarelin, hirsutism management, 1040
- National Breast and Cervical Cancer Early Detection Program (NBCCEDP), USA, 150
- natural killer cells, 924
- necrotizing fasciitis, 315–16
management, 316
- negative predictive value, 123
- Neisseria gonorrhoeae*,
see gonorrhoea; pelvic inflammatory disease
- neoadjuvant therapy, breast cancer, 683
- neosalpingostomy, 615
- neovagina creation, 582–3
- neurogenic pain, 52
- neuropathic pain, 831, 833
- neurosyphilis
diagnosis, 332
treatment, 332
- nipple
anatomy, 692
aspirate fluid, 715
discharge embryology, 692

Index

- nipple (cont.)
 evaluation, 703
 galactorrhea, 930
 inversion, 702
 nociceptive pain, 52
 nocturia, 452
 nocturnal enuresis, 452
 non-coital sexual pain disorder, 79
 nonoxynol-9, 968
 non-steroidal anti-inflammatory drugs (NSAIDs), 69, 285
 abnormal uterine bleeding management
 menorrhagia, 117
 perimenopausal, 1013
 adverse effects, 69, 283
 cancer pain, 839
 chronic pelvic pain, 69
 dysmenorrhea, 556–7
 leiomyoma, 238
 perioperative pain, 283
 premenstrual syndrome, 40
 norelgestromin, 964
 NSAIDs, *see* non-steroidal anti-inflammatory drugs
 nucleic acid amplification tests
 chlamydia, 327
 gonorrhea, 321
 nucleoside reverse transcriptase inhibitors, 364
 nutrition, *see* diet
 nutritional status, preconception counseling, 140–1
 obesity, 126, 134–5
 counseling, 134–5
 preconception counseling, 141
 definition, 289
 endometrial cancer
 association, 756, 1009
 evaluation, 134
 health impact, 134
 incidence, 290
 management, 1035–7
 postoperative, 290
 preoperative, 289–90
 surgical treatment, 135, 1036–7
 maternal obesity, 1026
 miscarriage relationship, 922
 pharmacotherapy, 135
 PCOS association, 1025–6, 1031, 1035–7
 pseudo-Cushing syndrome and, 1064
 recurrent pregnancy loss relationship, 924
 screening, 134
 surgical implications, 304, 384
 urinary incontinence association, 419
 obstetric trauma, 406,
see also perineal trauma
 during childbirth
 fecal incontinence association, 433, 435–6
 obturator nerve injury, 628
Oenothera, *see* evening primrose oil
 OHSS, *see* ovarian hyperstimulation syndrome
 oligomenorrhea, PCOS, 1031–2
 onabotulinumtoxinA (botulinum toxin A) incontinence management, 413
 oncogenes, 843–4, 849–50
CMYC, 850
HER2/Neu, 686–7
KRAS, 849
PIK3CA, 849
 ondansetron, 68
 oocyte, 973
 cryopreservation, 894
 donor oocytes, 894–5
 quality decline, 1018
 oocyte retrieval, 890–1
 oophorectomy, *see also* bilateral salpingo-oophorectomy
 adolescents, 578
 prophylactic, 680, 793, 847–8
 operant conditioning theory of pain, 570
 opioids, 70
 addiction, 832
 cancer pain, 835–9
 dosing strategies, 838
 chronic pelvic pain, 69–70
 treatment evaluation, 70
 fentanyl, 837
 hydromorphone, 837
 incomplete cross-tolerance, 833
 intraspinal therapy, 835–6
 methodone, 837
 morphine, 836–7
 oxycodone, 837
 perioperative pain, 283
 physical dependence, 832
 rotation, 833, 838–9
 side-effects, 70, 837
 oral contraceptives, 961–4
 abnormal uterine bleeding management, 1014
 anovulatory bleeding, 118
 menorrhagia, 117–18
 perimenopausal, 1011–2
 adolescent contraception, 552–6
 breast cancer association, 963
 cardiovascular risks, 962
 contraindications, 961
 endometrial cancer protection, 757, 1014, 1039–40
 endometriosis treatment, 215
 hirsutism management, 548, 1040
 leiomyoma management, 237
 leiomyoma risk relationship, 226
 non-contraceptive health benefits, 556, 961–2
 ovarian cancer risk relationship, 792, 1014
 pelvic inflammatory disease relationship, 1016
 perimenopausal women, 1013–4, 1020
 abnormal bleeding management, 1011–2
 endometrial cancer reduction, 1014
 fracture prevention, 1014
 lipid profile responses, 1014
 ovarian cancer reduction, 1014
 vasomotor symptom management, 1015
 premenstrual syndrome management, 38
 progestin-only pill, 967
 side-effects, 963–4
 orgasmic disorder, 79
 following female genital mutilation, 106
 treatment, 81
 osteomalacia, 14
 osteonecrosis of the jaw, 20
 osteoporosis, 1–2, 988, 991–3,
see also fracture
 associated diseases, 7
 associated medications, 7
 challenges, 24–5
 definition, 2
 diagnosis, 6–14, 989
 biochemical markers of
 bone turnover, 11, 14
 bone mass, 6, 8–9
 bone mineral density, 11
 laboratory evaluation, 11–14
 risk factor role, 6–10
 economic costs, 24
 epidemiology, 2
 HIV infection and, 364
 lifestyle recommendations, 14, 991
 exercise benefits, 17–18
 nutritional requirements, 14–17
 pathogenesis, 4–6
 perimenopausal management, 1016
 pharmacological therapies, 18–24
 bisphosphonates, 18–21, 993
 calcitonin, 23
 combination therapy, 24
 denosumab, 23
 during pregnancy and lactation, 24
 estrogen, 21–2, 46, 992
 patient selection, 18
 selective estrogen receptor modulators, 22, 993
 strontium ranelate, 23–4
 teriparatide (recombinant PTH), 23, 993
 timing of onset, 18
 risk factors, 1015–6
 secondary causes, 7, 11–14
 hyperprolactinemia, 930
 ovarian cancer
 biological therapy, 802–3
 chemotherapy, 798–802
 advanced stage disease, 799–800
 early-stage disease, 798–9, 801
 intraperitoneal chemotherapy, 800–1
 neoadjuvant chemotherapy, 797
 recurrent disease, 802–5
 clinical presentation, 793–4
 consolidation therapy, 802
 cytoreductive surgery, 794–8
 interval debulking, 797
 diagnosis, 794
 during pregnancy, 856–7
 elderly patients, 48
 epidemiology, 790
 age-specific incidence, 48, 617
 age-specific mortality, 48
 future directions, 807
 genetics, 845–8
BRCA genes, 846
 family history, 845–6
 germ cell tumors, 806
 high-risk criteria, 800
 histological types, 790
 imaging, 197–200
 infertility relationships, 878
 metastatic cancer to the ovary, 806
 oral contraceptive protective effect, 1014
 PCOS association, 1033
 prognostic factors, 797–8
 age, 797
BRCA status, 798
 DNA ploidy, 798
 histology, 797
 performance status, 797
 residual disease, 797
 tumor grade, 797
 prophylactic oophorectomy, 793, 847–8
 radiation therapy, 803
 recurrent disease, 803–5
BRCA and *BRCAoid* disease, 805
 chemotherapy, 802–5

- risk factors, 790–2
 age, 790
 dietary factors, 791
 ethnicity, 791
 exposures, 791–2
 family history, 791
 sarcoma, 806
 screening, 792–3
 general population, 792
 genetic screening, 847
 high-risk population, 792–3
 second-look surgery, 801–2
 spread, 794
 staging, 794–5
 survival by stage, 795
 stromal cell tumors, 806
- ovarian cysts, 196,
see also polycystic ovary
 syndrome
 adolescents, 575
 cystectomy, 578
 elderly patients, 48
 management, 617–18
 physiological cysts, 196
 precocious puberty
 association, 509
- ovarian drilling, 876
 PCOS management, 953, 1039
- ovarian endometrioma, 206, 210
 treatment, 219
- ovarian factor infertility, 868
 diagnosis, 873
 treatment, 876–7
- ovarian hyperandrogenism, 510
- ovarian hyperstimulation
 syndrome (OHSS),
 891–3, 953
 clinical features, 892
 complications, 892
 hospitalization, 892
 fluid management, 892
 paracentesis, 892
 outpatient management, 892
 pathophysiology, 892
 PCOS association, 1038
 prevention, 892–3
 risk factors, 892
- ovarian pregnancy, 263
 diagnosis, 261
- ovarian reserve,
see also premature
 ovarian insufficiency
 assessment, 874, 886–7
 decline, 1018
 recurrent pregnancy loss
 relationship, 922
- ovarian stimulation, 887–8,
see also ovarian
 hyperstimulation
 syndrome
 clomiphene citrate, 888
 natural cycle IVF, 887–8
- ovarian suspension, 218
- ovarian torsion, *see* adnexal
 torsion
- ovarian tumors, *see also* ovarian
 cancer; ovarian cysts
 detection, 954
 precocious puberty
 association, 509
- ovaries, *see also* premature
 ovarian insufficiency
 benign conditions, 194–7
 follicle, 973, 976–8
 dominant follicle, 978–9
 perimenopausal changes,
 1006
 hormonal changes during
 menstrual cycle, 976–8
- imaging, 190
 maturation, 496, 498, 501
 normal anatomy, 190
- overactive bladder, 411,
see also urinary
 incontinence
- ovulation, 866, 978, 980
 detection, 38–40, 952
 failure, *see* anovulation
 premenstrual syndrome
 treatment, 38–40
- oxandrolone, 529
- Oxford score for pelvic floor
 muscle strength, 406
- oxybutynin, 420
 urinary incontinence
 management, 412
- oxycodone, 837
- $p16^{INK4a}$, 852
- p53 protein, 844
- pad test, 455–6
 indications, 456
 types of, 455–6
- Paget disease, extramammary,
 734
- pain, 52, *see also* cancer pain;
 pelvic pain; *specific
 conditions*
 Cartesian theory, 570
 chronic, 52
 cognitive theories, 570
 gate theory, 571
 localization, 53–5
 neurogenic, 52
 neuropathic, 831, 833
 neurotransmitters, 571
 nociceptive, 52
 onset, 56
 operant conditioning theory,
 570
 perioperative pain
 management, 283
 postoperative, 303
 psychological perspectives,
 570–1
 radiation, 55
 severity assessment, 55–6
 somatic, 831
 stimuli, 52
 visceral, 55, 831
- pain mapping, 53, 57
 laparoscopic, 59
- painful bladder syndrome,
see interstitial cystitis/
 painful bladder syndrome
- painful sexual intercourse,
see dyspareunia
- palliative care
 surgery, 298
 vulvar carcinoma, 733
- PALM-COEIN classification,
 112–13
- Papanicolaou (Pap) test, 149–50,
see also cervical cancer
 screening
 abnormal results, 374
 management of, 154–61
- paracentesis, ovarian
 hyperstimulation
 syndrome management,
 892
- parathyroid hormone (PTH)
 elevated, 14, 23
 teriparatide (recombinant
 PTH), osteoporosis
 management, 23, 993
- parental age, 139
- parity
 leiomyoma risk relationship,
 224–5
 ovarian cancer protection,
 791
 urinary incontinence and, 418
- paroxetine, premenstrual
 syndrome treatment, 34
- PARP (poly-ADP ribose
 polymerase) inhibitors,
 805
- paternal age, 139
- patient positioning
 hysteroscopy, 607
 laparoscopy, 605–7
 robotic surgery, 608–9
- patient-controlled analgesia,
 283–5
- PCI mutations, 901
- PCOS, *see* polycystic ovary
 syndrome
- peak bone mass, 4
- Pearl index, 958
- pediatric patients,
see also adolescents
 adnexal masses, 574–8
 differential diagnosis, 584
 management, 576–8
 physical examination, 575
- adnexal torsion, 578–80
 evaluation, 579
 management, 580
- bladder injuries, 565, 567
- bowel injuries, 565
- genital injuries, 563–70
 clinical features, 563–5
 evaluation, 565–7
 prevention, 570
- treatment, 568
- genital neoplasms, 545
- gynecological examination,
 534–7
 appropriate techniques,
 536–41
 documentation, 537
 indications, 548
 patient positioning, 535
 specimen collection, 537
- inflammatory vulvar
 conditions, 545
- labial adhesions, 544
- lichen sclerosus, 542–3
- sexual abuse, 564–5
- urethral injuries, 565–6
- urethral prolapse, 545
- vaginal injuries, 564–5
- vulvar ulcers, 543–4
- vulvovaginitis, 540–52
 causes, 552
 management, 542
 risk factors, 550
- pediculosis pubis, 341–2
 clinical features, 341
 diagnosis, 341
 treatment, 342
- pelvic congestion syndrome, 64
- pelvic diaphragm, 399–402
- pelvic floor, *see also* pelvic
 support
 examination, 406
 muscle training, 411, 414, 419
 Oxford score for muscle
 strength, 406
 tension myalgia, 572
- pelvic inflammatory disease
 (PID), 349
 chlamydia association, 325–6
- chronic pelvic pain
 association, 52, 63–4
- diagnosis, 351–6
 cervical examination, 352
 clinical diagnosis, 352, 354
 clinical signs and symptoms,
 351–3
 differential diagnosis, 351
 imaging studies, 354–6
 laboratory tests, 353–4
 specific criteria, 354
 supportive findings, 354
 vaginal examination, 351–2
- ectopic pregnancy association,
 254
- epidemiology, 349
- following female genital
 mutilation, 106
- gonorrhoea pathology, 320
- HIV relationship, 367
- hospitalization criteria, 356
- microbiology, 349–51
- oral contraceptive relationship,
 1016
- risk factors, 351
- sequelae, 358

Index

- pelvic inflammatory disease (PID) (cont.)
 STD associations, 354
 STD screening, 357
 treatment, 356–8
 antibiotic regimens, 356–7
 counseling, 357
 sex partner, 357
- pelvic mass referral guidelines, 793
- pelvic organ prolapse, 403–4, 460–1
 clinical examination, 462
 imaging, 462
 quantification (POP-Q), 406–7, 461
 recording measurements, 407
 staging, 407
 symptoms, 460
 types of, 462
- pelvic pain, 207, *see also* chronic pelvic pain
 adolescents, 556
 endometriosis association, 206
 gastrointestinal causes, 584
 gynecological causes, 584
 leiomyoma manifestations, 230–1
 musculoskeletal causes, 584
 urological causes, 572
- pelvic support, 399,
see also pelvic floor abnormalities, 403–6,
see also pelvic organ prolapse
 anal incontinence, 405–6
 connective tissue injury, 405
 levator ani muscle injury, 403–4
 urinary incontinence, 405
- anal sphincters, 401–2
 endopelvic fascia, 401
 levator ani, 399–401
 normal anatomy, 399
 pelvic diaphragm, 399–402
 perineal body, 401
 perineal membrane, 401
 striated urogenital sphincter, 401
- penicillin allergy, 284
 pentosan polysulfate, 66
 percutaneous epididymal sperm aspiration, 913
- pergolide
 hyperprolactinemia management, 935
 valvular heart disease association, 935, 938–9
- perianal intraepithelial neoplasia, 378
 HIV association, 366
- perimenopause, 1004,
see also menopausal symptoms; menopause
- abnormal uterine bleeding, 1008–13
 causes, 1008
 evaluation, 1008–11
 medical management, 1010–4
 surgical management, 1013
- age of, 1006
 contraceptive formulations, 1010
 definition, 1005
 depression, 1016–7
 endocrine changes, 1006–7
 fertility, 1017–9
 health maintenance and screening, 1019
 lifestyle intervention, 1019–20
 HT, 1020–1
 recommendations, 1019
- hot flashes, 1014–5
 management, 1015
- menstrual irregularity, 1008
- oral contraceptive benefits, 1013–6, 1020
 abnormal bleeding management, 1011–2
 contraception, 1013–4
 endometrial cancer reduction, 1014
 fracture prevention, 1014
 lipid profiles, 1014
 ovarian cancer reduction, 1014
 vasomotor symptoms, 1015
- osteoporosis, 1016
- ovarian follicle changes, 1006
- presentation, 1004
- sexual dysfunction, 1015
- symptoms, 1005
- perineal body, 401
- perineal lacerations, 564
 treatment, 568
- perineal membrane, 401
- perineal trauma during childbirth, 405–6
 classification, 405
 fecal incontinence association, 436
- perioperative complications
 cardiac complications, 290–2
 pain management, 283
- persistent genital arousal disorder, 79
- pessaries, urinary incontinence management, 414
- Pfannenstiel incision, 299
- Philadelphia chromosome, 843
- photoplethysmography, 81
- Phthirus pubis*, *see* pediculosis pubis
- physical activity, *see* exercise
- phytoestrogens, 87–90, 989–90
 breast cancer risk relationship, 90
- menopausal symptom management, 88–90
- PIK3CA, 849
- pimecrolimus, 270
- pioglitazone, 1038
- piriform muscle
 evaluation, 58
 spasms, 572
- pituitary adenomas, 870, 901, 932–3,
see also prolactinomas
 secondary amenorrhea relationship, 947–8
- pituitary function, 976
- placental site trophoblastic tumor, 821–2
 clinical features, 821–2
 diagnosis, 822
 pathology, 821
 treatment, 822
- PlasmaJet, 594
- PLISSIT model, 80
- pneumonia, 293
- podofilox, genital wart treatment, 376
- POI, *see* premature ovarian insufficiency
- Poland syndrome, 526
- polycystic ovary syndrome (PCOS), 868, 1024
 adolescence, 1032
 androgen excess, 1026–31
 as an inherited disorder, 1029–30
 cardiovascular disease association, 1032–3
 prevention, 1039
 clinical features, 1030–2
 acanthosis nigricans, 1031
 anovulation, 1029, 1031
 infertility, 1031
 menstrual irregularity, 1031
 polycystic ovary ultrasound morphology, 1032
- diabetes association, 1032
 management, 1039
 diagnosis, 116, 948, 1034–5
- dysfunctional gonadotropin metabolism, 1026
- epidemiology, 1024
- gynecological cancer association, 1033–4, 1039–40
- hirsutism management, 1040–1
- imaging, 196
- infertility treatment, 876, 1035–9
 aromatase inhibitors, 1038
 clomiphene citrate, 1038
 corticosteroids, 1038–9
 gonadotropins, 1038
 insulin-sensitizing agents, 1037–8
- obesity control, 1035–7
 surgery, 1039
- insulin resistance, 1024–5
 management, 1035
 amenorrhea, 952–3
 metformin, 548–9, 1037–8
- metabolic changes during pregnancy, 1030
- metabolic syndrome and, 548
- obesity association, 1025–6, 1031
- polyglandular syndrome, 951, 1056
- positive predictive value, 123
- positron emission tomography (PET), 189
 breast cancer screening, 713–14
- postablation tubal sterilization syndrome, 674
- postcoital test, 871, 907
- posterior tibial nerve stimulation, 413
- postmenopausal women,
see also geriatric population; menopausal symptoms
 abnormal cervical cancer screening results, 160
 clinical management, 999–1000
 colposcopy, 180
 increasing numbers, 1005
 uterine bleeding, 47, 757
 endometrial cancer association, 758
 hysteroscopic evaluation, 663
 uterine sarcoma association, 770
- postmenopause, 1005
- postoperative complications,
see also surgical site infection; *specific conditions*
 obese patients, 290
 pulmonary complications, 293
 preoperative predictors, 292–3
 thromboembolism, 286–8
 management, 286–8
 prophylaxis, 285–6
 risk stratification, 291
- postoperative pain, 303
- postpartum contraception, 970
- postpartum thyroiditis, 1050–1
 treatment, 1052
- post-traumatic stress disorder,
 following female genital mutilation, 107
- potassium sensitivity test, 62–3
- Prader–Willi syndrome, 526, 901
- pramipexole, 935
- precocious puberty, 494, 503, 506–7

- central(CPP), 506–9
 differential diagnosis, 507–9
 CNS lesions associated with, 508
 contrasexual, 506
 definition, 494–5, 506, 517
 diagnosis, 511–14, 517
 history, 511
 laboratory studies, 512–14
 physical examination, 511–12
 isolated/incomplete, 506, 510–11
 premature menarche, 510–11
 premature pubarche/adrenarche, 498
 premature thelarche, 510
 isosexual, 506
 non-progressive, 506
 peripheral (PPP), 506, 509–10, 516
 differential diagnosis, 509–10
 prevalence, 507
 prognosis, 517
 adult issues, 517
 psychosocial impact, 517
 slowly progressive, 506
 treatment, 514–17
 GnRH agonists, 515–16
 idiopathic CPP, 515
 outcomes, 516
 who to treat, 515
 preconception counseling, 138
 chromosomal abnormality risk, 139
 chronic medical conditions, 141–3
 environmental exposures, 143–4
 genetic disorders, 139–40
 consanguinity, 140
 ethnic/racial background significance, 140
 genetic history taking, 138
 infections, 143
 medications contraindicated in pregnancy, 139
 nutritional status, 140–1
 parental age issues, 139
 pregnancy, *see also* ectopic pregnancy
 bone mass changes, 24
 cancer during, 854–5, 860–2
 breast cancer, 855–6
 cervical cancer, 753, 856
 chemotherapy, 861
 colorectal cancer, 860
 diagnostic workup, 860
 effects on fetal outcome, 861
 Hodgkin disease, 859–60
 hormonal therapy, 861
 melanoma, 859
 ovarian cancer, 856–7
 psychosocial impact, 862
 radiation therapy, 861
 surgical management, 861
 thyroid cancer, 858–9
 chlamydial infection, 327
 coercion, 95
 colposcopy, 178–80
 endometrial cancer protection, 757
 female genital mutilation issues, 104
 following chemotherapy for gestational trophoblastic disease, 827
 following endometrial ablation, 675–6
 gonorrhea pathological effects, 320
 herpes simplex virus infection, 337
 transmission to neonate, 337–8
 hyperthyroidism, 1050
 diagnosis, 1050–1
 treatment, 1051–2
 hypothyroidism, 1049
 hysteroscopy complications, 675–6
 intimate partner violence during, 94
 outcomes, 95–6
 leiomyoma effects, 232–4, 238
 medications contraindicated during, 139
 PCOS and, 1030
 secondary amenorrhea and, 944
 SSRI safety, 36
 testing, 944
 unexpected discovery of during surgery, 302
 pre-implantation genetic screening, 894
 premature ovarian insufficiency (POI), 527–8, 868, 950–1, *see also* ovarian reserve
 infertility management, 876–7
 treatment, 950–1
 premenstrual dysphoric disorder (PMDD), 27
 clinical features, 28–9
 diagnosis, 29
 differential diagnosis, 29–31
 epidemiology, 27
 natural history, 30
 pathogenesis, 27–8
 serotonin, 27–8
 sex steroids, 28
 risk factors, 27
 symptoms, 28
 treatments, *see* premenstrual syndrome
 premenstrual syndrome (PMS), 27, *see also* premenstrual dysphoric disorder
 clinical features, 28–9
 diagnosis, 29
 differential diagnosis, 29–31
 epidemiology, 27
 future research, 41
 herbal therapies, 32, 86
 natural history, 30
 non-pharmacological treatments, 30–3
 dietary modification, 30
 dietary supplements, 32
 exercise, 30
 lifestyle modifications, 30
 psychotherapy, 30–1
 sleep hygiene, 30
 stress reduction, 30
 pathogenesis, 27–8
 genetic factors, 28
 serotonin, 27–8
 sex steroids, 28
 pharmacological treatments, 34, 888
 alprazolam, 40
 busiprone, 38
 clomipramine, 38
 dosage regimens, 37
 duloxetine, 38
 NSAIDs, 40
 ovulation suppression, 38–40
 SSRIs, 33–7, 41
 spironolactone, 40
 venlafaxine, 38
 risk factors, 27
 symptoms, 28
 treatment guidelines, 40–1
 Prentif cervical cap, 968
 preoperative management, 605–7, *see also specific conditions*
 antimicrobial prophylaxis, 283–5, 301
 endocarditis prophylaxis, 284, 291
 bowel preparation, 284–5, 301
 diabetes, 289
 discussion and informed consent, 282–4, 297–300
 presenting risk information, 301
 fasting, 300
 laboratory evaluation, 282
 medical history, 281–2
 obesity, 289–90
 skin preparation, 301
 thromboembolism prophylaxis, 285–6, 301
 presacral neurectomy, 630–1
 endometriosis treatment, 66
 preventive medicine, 122
 alcohol misuse, 128–9
 anemia, 131
 definitions, 122–3
 diabetes, 133
 diet and nutrition, 126–7
 drug abuse, 129
 hearing loss, 124–5
 household and recreational injuries, 129–30
 hypertension, 133–4
 immunizations, 123–4
 lipid disorders, 131–2
 motor vehicle accidents, 130
 obesity, 134–5
 physical activity, 126
 skin cancer, 125–6
 smoking cessation, 127–8
 suicide and depression, 130–1
 thyroid disorders, 132
 visual screening, 125
 primary amenorrhea, 521–2, 528–9
 etiology, 522
 primary hyperparathyroidism, 14
 primary prevention, 122
 progesterone, 943, *see also* progestins
 delayed puberty management, 530–1
 ectopic pregnancy diagnosis, 258
 leiomyoma etiology, 229
 luteal support in IVF, 891
 menstrual cycle regulation, 978, 981
 ovulation prediction, 873
 perimenopausal changes, 1007
 PCOS management, 952
 premenstrual syndrome treatment, 39
 recurrent pregnancy loss and, 921–2
 progesterone-only contraception, bone density impact, 14
 progestins, *see also* contraception
 abnormal uterine bleeding management, 117–18, 1014
 perimenopausal, 1012
 adverse effects, 215
 delayed puberty management, 530–1
 endometrial cancer protection, 998–9
 endometrial cancer treatment, 761
 endometrial hyperplasia management, 758
 endometriosis treatment, 215
 injectable progestins, 215
 intrauterine progestin, 215
 oral progestins, 215
 leiomyoma risk relationship, 226
 pharmacological profile, 39
 PCOS management
 amenorrhea, 952

Index

- prolactin, 929, *see also* hyperprolactinemia
 biological functions, 929
 regulation, 929–30
 prolactinomas, 527, 868, 901, 931–2, 948,
see also hyperprolactinemia
 surgical removal, 936–7
 propylthiouracil, 1051
 proto-oncogenes, 843–4
 pseudo-addiction, 832
 pseudo-Cushing syndromes, 1064
 pseudohermaphroditism, 903
Pseudomonas aeruginosa, 309
 psychological dependence, 69
 psychotherapy
 chronic pelvic pain, 71
 irritable bowel syndrome, 68
 premenstrual syndrome, 30–1
PTEN, 850–1
 pubarche, 494, 498, 520
 premature, 498
 puberty, 493–4, 521,
see also delayed puberty;
 precocious puberty
 body composition changes, 502
 bone changes, 502–3
 brain changes, 502
 clinical signs of, 498–501
 males, 501
 early, 506, *see also* precocious
 puberty
 constitutional, 506
 fetal, childhood and adolescent
 endocrinology, 495–6
 hormonal changes, 496–7, 513
 GnRH, 496
 gonadarche, 496
 gonadotropins, 496
 inhibin, activin and
 follistatin, 497
 ovarian maturation, 496
 racial differences, 494, 521
 sex hormone-binding
 globulin, 497
 somatic growth, 501–2
 timing determinants, 497–8
 trends, 494, 517, 521
 year of onset ranges, 521
 pubic hair development, 498,
 520, *see also* pubarche
 males, 500
 puborectalis muscle, 400, 433
 pubovisceral muscle, 400
 pudendal nerve, 401
 pudendal nerve terminal motor
 latencies, 439
 pulmonary complications, 292–3
 preoperative predictors, 292–3
 pulmonary edema, 293
 pulmonary embolism, 285, 293,
 303–4, *see also* thrombo-
 embolism
 management, 287–8
 punctations, 170, 174
 pyoderma, 308
 pyoderma fistulans, 309
 pyospermia, 907
 pyrexia, following surgery, 303
 quality-of-life evaluation, 452–4
 quinagolide, 935
 radiation therapy
 breast cancer, 682
 following lumpectomy, 682
 postmastectomy irradiation,
 682–3
 cervical cancer, 750–1
 adjuvant radiotherapy, 751
 chemoradiation, 751
 contraindications, 682
 during pregnancy, 861
 endometrial cancer, 761–5
 recurrence management,
 764–5
 fallopian tube carcinoma, 784
 hyperprolactinemia, 937
 ovarian cancer, 803
 side-effects, 683
 uterine sarcoma
 palliative therapy, 776
 radiotherapy as risk factor,
 770
 vaginal cancer, 741
 vulvar carcinoma, 729–30, 733
 radioiodine treatment, 1051
 raloxifene
 breast cancer prophylaxis, 680
 osteoporosis management, 22,
 993
 random periareolar fine-needle
 aspiration, 716
 RANK ligand inhibitor, 993
 RANKL, 23
 RAS genes, 844, 849
 reactive oxygen species, semen,
 907
 recreational injury prevention,
 129–30
 rectovaginal fistulae, 477–88
 clinical features, 481
 diagnosis, 481–2
 etiology, 477–80
 following female genital
 mutilation, 106
 management, 482–8
 complicated fistulae, 485–8
 surgical treatment, 482–5
 recurrent pregnancy loss (RPL),
 918
 anatomical factors, 922–3
 acquired uterine anomalies,
 923
 congenital uterine
 anomalies, 922–3
 definition, 918
 endocrinological factors,
 921–2
 abnormal glucose
 metabolism, 922
 decreased ovarian reserve,
 922
 hyperprolactinemia, 922
 hypothyroidism, 922
 luteal phase deficiency,
 921–2
 evaluation algorithm, 919–20
 genetic factors, 919–21
 aneuploidy, 921
 structural, 921
 immunological factors, 923–4
 alloimmune factors, 924
 antinuclear antibodies, 924
 antiphospholipid antibodies,
 923
 lifestyle factors, 924
 alcohol consumption, 924
 obesity, 924
 tobacco smoking, 924
 recurrence risk, 919
 red clover, 89–90
 red degeneration, 234
 Reid colposcopic index, 174–5
 reinfublation, 109
 relaxation therapy, chronic pelvic
 pain, 71
 renal failure, 901
 renin–angiotensin–aldosterone
 axis, 1058–9
 rescue medication, 832
 resectoscopes, 600
 retrograde ejaculation, 904
 treatment, 914
 retrograde menstruation, 204–5
 retroperitoneal
 lymphadenectomy,
see lymphadenectomy;
 laparoscopic
 lymphadenectomy
 retropubic transvesical
 vesicovaginal fistula
 repair, 472
 risedronate, 993
 robotics, 598–9, 632–42
 drawbacks, 641
 fertility-sparing procedures,
 636
 patient positioning, 608–9
 robotic-assisted radical
 hysterectomy, 632–9
 clinical findings, 632–5
 complications, 635
 history, 632
 surgical technique, 636–9
 robotic-assisted trachelectomy,
 640–1
 surgical set-up, 608–9
 instrument layout, 609
 personnel, 609
 Rokitansky–Kuster–Hauser
 syndrome, *see* Mayer–
 Rokitansky–Kuster–
 Hauser syndrome
 ropinirole, 935
 rosiglitazone, 1038
 Rubin and Barbo colposcopic
 assessment system, 174,
 176
 sacral nerve stimulation, 447–8
 sacral neuromodulation, 413
 safety planning, 97–8
 saline distention medium, 601
 saline infusion sonography,
 114–15
 perimenopausal abnormal
 uterine bleeding
 evaluation, 1009–10
 salpingectomy, 614
 ectopic pregnancy treatment,
 261–2, 614
 salpingitis, 352, *see also* pelvic
 inflammatory disease
 chlamydia association, 326
 ectopic pregnancy association,
 255
 salpingitis isthmica nodosa, 867
 salpingocentesis, ectopic
 pregnancy treatment, 262
 salpingoscopy, 615
 salpingostomy, ectopic
 pregnancy treatment,
 261, 614
 sarcoma, *see* ovarian cancer;
 uterine sarcoma; vaginal
 sarcoma
 sarcoma botryoides, 545
Sarcoptes scabiei, *see* scabies
 Savage syndrome, 528
 scabies, 340–1
 clinical features, 341
 diagnosis, 341
 treatment, 341
 scar endometriosis, 208
 scissors, 595
 screening, 122, 146–7,
see also preventive
 medicine; *specific
 conditions*
 equity of access, 147
 potential harms, 122
 screening test evaluation, 122
 Secca radiofrequency procedure,
 448
 secondary amenorrhea, 942–4
 causes, 942–4
 hyperprolactinemia, 930
 classification, 947
 clinical history and evaluation,
 944–5
 definition, 944
 diagnosis, 943, 945–8
 epidemiology, 944
 management, 948–55
 bone protection, 949, 955
 congenital adrenal
 hyperplasia, 953–4
 Cushing syndrome, 954

- fertility, 949–50
hypergonadotropic
 hypoestrogenism, 950–1
hyperprolactinemia, 951–2
hypothalamic amenorrhea, 949–50
outflow causes, 954–5
ovarian/adrenal neoplasms, 954
PCOS, 952–3
thyroid disease, 952
secondary prevention, 122
seizure disorders, preconception counseling, 142
selective estrogen receptor modulators (SERMs)
 osteoporosis management, 22, 993
selective glucocorticoid receptor agonists, 1061
selective norepinephrine reuptake inhibitors, 1015
selective progesterone receptor modulators (SPRMs), leiomyoma management, 241
selective serotonin reuptake inhibitors (SSRIs)
 adverse effects, 35–6
 sexual side-effects, 35–6
 drug interactions, 37
 hot flash management, 1015
 premenstrual syndrome treatment, 33–7, 41
 discontinuation effects, 36
 during pregnancy and breast feeding, 36
 relapse rate, 36
 sexual dysfunction relationships, 76
semen analysis, 874, 887, 906–8, *see also* sperm fructose content, 907 leukocyte testing, 907 reactive oxygen species, 907 sperm count, 906
sensitivity, 123
 program sensitivity, 163
 test sensitivity, 163
sentinel lymph node biopsy
 breast cancer, 682
 cervical cancer, 748
 vulvar carcinoma, 731–2
sepsis, 303, 393
 diagnostic criteria, 393
septic shock, 393, 395
 etiology, 388–91
 management, 391–3
 treatment, 392–6
serotonin, premenstrual syndrome pathogenesis, 27–8
serous cystadenoma, 197
Sertoli cells, 899
sertraline, premenstrual syndrome treatment, 34
Sestamibi scintimammography, 714
sex hormone-binding globulin, 497
sexual abuse
 chronic pelvic pain association, 51, 570
 pediatric patients, vaginal injuries, 564–5
sexual arousal disorder, 78–9
 treatment, 81
sexual aversion disorder, 78
sexual dysfunction, *see* female sexual dysfunction
Sexual Function Questionnaire (SFQ), 82
sexual response, 77–9, *see also* female sexual dysfunction
sexually transmitted diseases/ infections (STDs/STIs), *see also specific diseases*
 adolescent patients, 539
 prevention, 551
 epidemiology, 318–19
 trends, 318–19
 pathogens, 319
 spectrum, 318
Sheehan syndrome, 868
shoulder pain, endometriosis, 207
sickle cell disease, 140
sildenafil (Viagra), 81
simulation training, 599
sinecatechin, 345
single incision laparoscopic surgery, 596–7
single-port laparoscopy, 631
skin cancer prevention, 125–6
 screening, 124
skin changes, *see also* vulvar conditions
 aging, perimenopausal, 988
 Cushing syndrome, 1062
 pigmentation in adrenal insufficiency, 1070
 precocious puberty and, 512
skin preparation for surgery, 301
sleep disturbance
 menopause, 987
 management, 990
 premenstrual syndrome, management, 30
smoking
 cervical intraepithelial neoplasia relationship, 177
 cessation, 127–8
 benefits, 128
 counseling, 127
 pharmacotherapies, 128
 preconception counseling, 143
leiomyoma risk relationship, 226
postoperative complications and, 293
recurrent pregnancy loss relationship, 924
screening benefits, 128
somatic pain, 831
sonohysterography (SHG), 188
 prior to IVF, 885
 tubal patency evaluation, 872
sorbitol distention medium, 601
soy products, 89
 isoflavone content, 89
specificity, 123
sperm
 acrosome reaction test, 907
 antisperm antibodies, 907
 fluorescent in situ hybridization, 908
 morphology, 906–7
 penetration assay, 907
 postcoital test, 907
 viability tests, 907
sperm count, 906
sperm motility, 903
sperm retrieval, 894
 epididymal sperm aspiration, 913
 testicular sperm extraction/ aspiration, 913–14
spermicides, 968
sphincteroplasty, fecal incontinence management, 443–5
spironolactone, 550
 hirsutism management, 1040
 premenstrual syndrome treatment, 40
squamous columnar junction, 147, 170, 173, 745
 colposcopy, 173
squamous cell carcinoma (SCC), *see also* vulvar carcinoma
 in situ, 723–4
 lichen sclerosis association, 277
 vaginal, 741
squamous intraepithelial lesions (SIL), 170, *see also* cervical intraepithelial neoplasia
 high-grade (HSIL), 159, 177
 colposcopic features, 177
 low-grade (LSIL), 156, 175–6
 colposcopic features, 176
squamous metaplasia, 170
SRY, 902
SSRI, *see* selective serotonin reuptake inhibitors
St. John's wort, 85–6
 adverse effects, 86
 depression treatment, 85–6
 drug interactions, 86
premenstrual syndrome management, 32, 86
stability genes, 844
Staphylococcus aureus, 307
 folliculitis, 308–9
 methicillin-resistant (MRSA), 308
 pyoderma, 308
staplers, 596
statins, 1039
sterilization, 612–13
 abnormal uterine bleeding relationship, 114
 ectopic pregnancy association, 254, 613
 hysteroscopic, 659–61
steroid treatment, *see also* corticosteroids
 cancer pain, 839
 lichen planus, 278
 side-effects, 270, 839
 vulvar conditions, 269–70
steroidogenesis, 1056, 1058
steroidogenic enzymes, 1057
steroidogenic acute regulatory protein (StAR), 903, 1056
 deficiency, 1077
Streptococcus agalactiae, vaginal, 383
Streptococcus pyogenes
 erysipelas, 308
 pyoderma, 308
stress incontinence, *see* urinary incontinence
striated urogenital sphincter, 401, 403
stroke, 963, 995
strontium ranelate, osteoporosis management, 23–4
subclinical papilloma infection, 170, *see also* human papillomavirus
suction curettage, hydatidiform mole, 817
suicide, 130–1
 prevention, 131
 risk factors, 131
superior hypogastric plexus neurolysis, 835
suprapubic transverse incision, 299
surgical drains, 304
surgical incision
 midline incision, 299
 suprapubic transverse incision, 299
surgical site infection, 303, 382, *see also* septic shock
 abscess, 387–8
 cellulitis, 387
 diagnosis, 386–8
 management, 387–9
 antibiotic choices, 389
 necrotizing infection, 387
 prevention, 384–5

Index

- surgical site infection (cont.)
 antibiotic prophylaxis, 385–6
 risk factors, 383–4
 inherent patient factors, 385
 vaginal microflora
 relationship, 383, 385
- surgical team, 304
- surrogacy, 895
- suturing instruments, 595–6
 clips, 596
 knot pusher, 596
 ligature, 596
 needle holder, 595
 needles, 595
 staplers, 596
 sutures, 595
- Swyer syndrome, 583
- sympathetic ganglionic blockade, 835
 hypogastric neurolysis, 835
- Synacthen (tetracosactide)
 stimulation test, 1061
- syphilis, 328–34
 clinical features, 330–1
 congenital syphilis, 331
 diagnosis, 331–2
 neurosyphilis, 332
 epidemiology, 328–30
 pathogenesis, 328, 330–1
 screening, 331–2
 treatment, 332–4
- systemic inflammatory response syndrome, 389–90, 393
 clinical manifestations, 393
 components of, 393
- T-ACE Questionnaire, 139
- tacrolimus, 270
- tamoxifen
 adverse effects, 651
 breast cancer prophylaxis, 680
 breast cancer treatment, 682–4
 metastatic disease, 686
 endometrial cancer
 association, 757
 endometrial cancer
 management, 764
 osteoporosis management, 22
 side-effects, 684
 use in pregnancy, 861
 uterine sarcoma association, 770
- tension-free vaginal tape, 426–7
- teriparatide (recombinant PTH), osteoporosis management, 23, 993
- tertiary prevention, 123
- testicular sperm aspiration, 914
- testicular sperm extraction, 914
- testicular torsion, 906
- testis biopsy, 908–10
- testosterone, 899, 1026–7
 levels, 529, 948, 1027
 age-related changes, 990
 hirsutism and, 548
- lichen sclerosus treatment, 276
- premenstrual syndrome
 pathogenesis, 28
- supplementation, 46
- sexual dysfunction
 management, 76, 80–1
- synthesis disorders, 903
- tetracosactide (Synacthen)
 stimulation test, 1060
- theca cells, 976
- thelarche, 494, 498, 520
 premature, 510
 evaluation, 512
- thiazolidinediones, 1038
- thromboembolism, 286–8, 303–4
 management, 286–8
 blood component therapy, 288
 deep vein thrombosis, 286–7
 pulmonary embolism, 287–8
 prophylaxis, 285–6, 301, 303–4
 low-dose heparin, 286
 low-molecular-weight heparins, 286
 mechanical methods, 286
 risk factors, 285, 995
 age, 995, 997
 oral contraceptives, 962–3
 transdermal contraceptive patches, 964–5
 risk stratification, 291
 septic shock etiology, 390
- thyroid crisis, 1050
 treatment, 1051
- thyroid disorders, 132, 512, 1047,
see also hyperthyroidism;
 hypothyroidism
 cancer, 1053
 clinical presentation, 1053
 diagnosis, 1053
 during pregnancy, 858–9
 epidemiology, 1053
 treatment, 1053
 infertility association, 869
 physiology, 1047
 screening, 132, 1049
 thyroid nodules, 1053
- thyroid-stimulating hormone (TSH)
 levels, 952
 screening, 1049
- thyroiditis, postpartum, 1050–1
 treatment, 1052
- thyroxine therapy, 1049
 in pregnancy, 1049
- tibolone, osteoporosis management, 22
- Tice model of breast cancer risk, 697
- tobacco smoking, *see* smoking
- tolerance, 69
- tolterodine, 420
 urinary incontinence management, 412
- total laparoscopic hysterectomy, 621–3
 cost effectiveness, 622
- indications and
 contraindications, 621–2
 preoperative evaluation, 622
 risks and benefits, 622
 surgical technique, 623
- total laparoscopic radical hysterectomy, 625–6
- total parenteral nutrition, 304
- TP53, 843–4, 851
- trachelectomy, robotic-assisted, 640–1
- tranexamic acid, menorrhagia management, 117
- transcutaneous electrical nerve stimulation, chronic
 pelvic pain management, 71
- transdermal contraceptive patch, 964–5
 adverse effects, 964–5
 detachment, 965
- transformation zone, 173, 745
 abnormal, 170, 173–4
 normal, 170, 173
- transforming growth factor- β_3 , leiomyoma etiology, 229
- transforming growth factor- β receptor 2, 852
- transrectal ultrasound (TRUS), 904, 908
- transsphenoidal pituitary surgery, 936–7, 1067
- transurethral resection of the ejaculatory duct (TURED), 913
- transvesical-transperitoneal vesicovaginal fistula repair, 472–4
- trastuzumab, 683
 metastatic breast cancer treatment, 686–7
- Treponema pallidum*, *see* syphilis
- Trichomonas vaginalis*, 350, 358,
see also trichomoniasis
- trichomoniasis, 339–40
 clinical features, 340
 diagnosis, 340
 epidemiology, 339
 pregnancy outcome relationship, 339–40
 treatment, 340
- trocars, 592–3
- troglitazone, 876, 1038
- T-score, 6, 10
- tubal factor infertility, *see* fallopian tube surgery; *specific procedures*
- tuberculosis, pelvic, 64
- tubo-ovarian abscess, 350, 352, 356
- tumor suppressor genes, 844, 850–2
FHIT, 852
p16INK4a (CDKN2A), 852
- PTEN, 851
TGFBR2, 852
TP53, 851
- Turner mosaic, 950
- Turner syndrome, 527, 529, 583
 pregnancy using donor oocytes, 951
- Tyrer–Cuzick model of breast cancer risk, 696
- Ulrich–Noonan syndrome, 903
- ultrasonic scalpel, 594
- ultrasound, 187–8
 adnexal masses, 575–6, 584, 617
 breast cancer screening, 709–10
 ectopic pregnancy diagnosis, 257–8
 fallopian tube carcinoma diagnosis, 783
 fecal incontinence assessment, 437–8
 leiomyoma detection, 234–6
 male infertility diagnosis, 908
 ovarian cancer screening, 792
 ovulation prediction, 873
 pelvic inflammatory disease diagnosis, 354–6
 perimenopausal abnormal uterine bleeding evaluation, 1009–10
 precocious puberty assessment, 514
 secondary amenorrhea evaluation, 945–7
- ureter injury
 during surgery, 302
 laparoscopy complications, 669–70
- urethra, 403
 bulking agents, 427
 functional tests, 457–8
 supports, 403, 405
 abnormalities, 405
- urethral injuries
 children, 565–6
 treatment, 569
- urethral prolapse, pediatric patients, 545
- urethrovaginal fistulae, 466,
see also urogenital fistulae
 surgical repair, 472
- urge incontinence, *see* urinary incontinence
- urinary catheters, 304
- urinary continence mechanism, 417–18
- urinary incontinence, 47, 405, 417–19, 451–2
 burden of, 417
 coital incontinence, 452
 diagnosis
 bladder diary, 454–5
 history, 451–2
 pad test, 455–6
 physical examination, 452

- postoperative differential diagnosis, 467
- urethral function tests, 457–8
- urine culture, 454
- urodynamic testing, 420–2, 456–7, 459–60
- videourodynamics, 458–9
- frequency, 452
- causes, 451
- insensible incontinence, 452
- mixed incontinence, 452
- nocturia, 452
- non-surgical treatments, 410, 419–21
- behavioral modification, 410–11
- bladder training, 419
- electrical stimulation, 419–20
- estrogen, 411, 990
- intravesical injection, 413
- lifestyle interventions, 410–11
- neuromodulation, 413
- pelvic floor muscle training, 411, 414, 419
- pessaries, 414, 419
- pharmacological treatments, 412–13, 420
- stress incontinence, 413–14
- urge incontinence, 411–13
- vaginal cones, 419
- perimenopausal, 1015
- postural incontinence, 452
- quality-of-life evaluation, 452–4
- risk factors, 418–19
- childbirth, 418
- forceps delivery, 418
- genetic factors, 419
- hysterectomy, 419
- obesity, 419
- stress incontinence, 417, 452
- surgical management, 422
- artificial urinary sphincter, 427
- Burch colposuspension, 424–5
- choice of procedure, 423–8
- Kelly–Kennedy plication, 423
- laparoscopic colposuspension, 425–6
- midurethral sling procedures, 426–7
- MMK procedure, 424
- needle suspension, 426
- pubovaginal sling procedures, 427
- surgical evidence, 422–3
- tension-free vaginal tape, 426–7
- urethral bulking agents, 427
- urge incontinence, 417, 452
- urinary symptoms, 452
- urodynamic stress incontinence, 417
- urinary tract infection, 454
- elderly patients, 46
- following female genital mutilation, 106
- urodynamic testing, 420–2, 456–7
- ambulatory urodynamics, 459–60
- urogenital fistula assessment, 468
- videourodynamics, 458–9
- uroflowmetry, 456
- urogenital atrophy, 44, *see also* vaginal atrophy
- perimenopausal, 988
- urogenital fistulae, 464
- clinical presentation, 466–7
- diagnosis, 467–8
- epidemiology, 464–6
- non-obstetrical fistulae, 465–6
- obstetric fistulae, 464–5
- etiology, 465
- following female genital mutilation, 106
- non-surgical management, 468–9
- pathogenesis, 466
- prevention, 468
- surgical correction, 469–77
- abdominal procedures, 470, 472–4
- grafting techniques, 471
- postoperative care, 477
- route of repair, 470
- success rates, 470–1
- urethrovaginal fistulae, 472
- vaginal procedures, 471–2
- vesicouterine fistulae, 475
- vesicovaginal fistulae, 471–4
- types of, 464
- urogynecology, 451
- uterine artery embolization, 241
- complications, 243
- leiomyoma management, 241–3
- risks to future pregnancy, 243
- treatment failure, 243
- uterine cancer, *see also* endometrial cancer; uterine sarcoma
- age-specific incidence, 48
- age-specific mortality, 48
- HT relationships, 998–9
- imaging, 191–4
- uterine factor infertility, 866–7
- diagnosis, 871
- treatment, 875
- uterine sarcoma, 193, 769
- classification, 769
- clinical features, 770–3
- adenosarcoma, 773
- carcinosarcoma, 770
- endometrial stromal sarcoma, 771–3
- leiomyosarcoma, 237, 770–2
- diagnosis, 773–5
- epidemiology, 769
- preoperative evaluation, 773–5
- prognosis, 777
- risk factors, 769–70
- staging, 759, 763
- treatment, 775–7
- adjuvant treatment, 776
- chemotherapy, 776–7
- radiotherapy, 776
- surgery, 775–6
- uterine septa
- hysteroscopic treatment, 655–8
- reproductive outcome, 657–8
- uterine synechia, 529
- uterosacral ligaments, 401–2
- uterovaginal prolapse, *see* pelvic organ prolapse
- uterus
- agenesis, 190
- aplasia, 529
- arcuate, 190
- benign conditions, 190–1
- bicornuate, 190
- changes at puberty, 499, 501
- congenital anomalies, 190–1
- recurrent pregnancy loss and, 922–3
- didelphus, 190
- imaging, 189–90
- prior to IVF, 885
- intrauterine adhesions, 659
- hysteroscopic lysis, 658–9
- reproductive outcome, 659
- normal anatomy, 189–90
- pain evaluation, 58
- perforation, 672, 676
- septate, 190, 922
- unicornuate, 190
- vaccinations, 123–4
- breast cancer, 716
- HPV, 379–80, 745–6
- vagina
- agenesis, 582
- anatomy, 736
- aplasia, 528
- biopsy, 174
- blood flow assessment, 81–2
- changes at puberty, 500–1
- colposcopy, 174
- neovagina creation, 582–3
- supports, 402–3
- vaginal aplasia, 529
- vaginal approach, 299–300
- vaginal atrophy, 44, 46
- management, 990
- perimenopausal, 988
- vaginal cancer
- adenocarcinoma, 737
- classification, 739
- diagnosis, 737–9
- epidemiology, 736
- histological types, 736
- lymphoma, 737, 742
- management, 740–2
- clear cell adenocarcinoma, 741
- invasive squamous cell carcinoma, 741
- lymphoma, 742
- melanoma, 742
- stage 0 disease, 740–1
- melanoma, 737, 742
- presentation, 738
- prognostic factors, 739
- recurrent disease, 742
- risk factors, 736–7
- sarcoma, *see* vaginal sarcoma
- staging, 739
- vaginal cones, 419
- vaginal contraceptive ring, 553, 965–6
- vaginal cuff dehiscence, 671–2
- vaginal discharge
- examination, 350, 353
- pH assessment, 350–1, 353
- vaginal endometriosis, 207, 209
- vaginal infections, 307
- bacterial vaginosis, 383
- diagnosis, 353
- HIV relationship, 367
- pelvic inflammatory disease relationship, 350
- candidiasis, 312–14
- diagnosis, 313–14
- management, 314–15
- risk factors, 314
- children, 540–52
- causes, 552
- management, 542
- risk factors, 550
- elderly patients, 46
- soft tissue infections, 308
- vaginal injuries
- children, 564–5
- examination, 567
- treatment, 568–9
- vaginal intraepithelial neoplasia (VAIN), 378, 737
- HIV association, 366
- management, 740–1
- vaginal lubricants, 81
- vaginal microflora, 307, 350, 382–3
- altered vaginal microflora, 350, 352, 382–3, 385
- assessment, 385
- bacterial combinations, 383
- pelvic inflammatory disease relationship, 350–1
- pH regulatory role, 382–3
- postoperative infection risk relationship, 383, 385
- preoperative assessment, 385
- vaginal sarcoma, 737
- management, 742
- vaginal septum, 190

Index

- vaginal warts, 345, 377
- vaginismus, 79
treatment, 81
- vaginitis, *see* vaginal infections
- varicoceles, 902, 906
classification, 906
treatment, 911–12
- vasal obstruction, 904
microsurgical reconstruction, 912–13
- vascular injury
laparoscopy complications, 627–8, 671, 676
management, 671, 676
- vasectomy, 904
reversal, 912–13
- vasography, 908
- vasovasostomy, 912
- Vecchietti neovagina creation
procedure, 582
- venlafaxine
hot flash management, 1015
premenstrual syndrome
treatment, 38
- venography, 287
- venous thromboembolism,
see thromboembolism
- Veress needle, 592
complications, 667
- Verneuil disease, 309
- vertebral fracture, 3–4, 9–10
- Vertebral Fracture Assessment (VFA), 9
- vesicouterine fistula repair, 475
- vesicovaginal fistulae, 464,
see also urogenital fistulae
hysterectomy association, 465–6
surgical repair, 471–2
retropubic transvesical
repair, 472
- transvesical-transperitoneal
repair, 472–4
- vestibulitis, 57, 279
- Viagra (sildenafil), 81
- videourodynamics, 458–9
- virtual reality training, 599
- visceral pain, 55, 831
- visual screening, 125
- vitamin A supplementation, 141
- vitamin B₆, premenstrual
syndrome management, 32
- vitamin D
deficiency, 14, 503
dietary reference intakes by life
stage, 16
osteoporosis management, 14–16
supplementation, 955, 1020
- vitamin E, premenstrual
syndrome management, 32
- Vitex agnus-castus*,
see chasteberry
- von Willebrand disease, 114, 288
- vulva, 267–8
anatomical variants, 268
biopsy, 46, 174, 269
colposcopy, 174
lymphatic drainage, 726–7
- vulvar carcinoma, 46, 277, 723
endoscopic inguinal
lymphadenectomy, 629
HPV association, 724
invasive disease, 726–33
inguinal-femoral lymph
node treatment, 730–1
primary lesion treatment, 732–3
lichen sclerosis association, 277, 723
- microinvasion, 731
- preinvasive disease, 723–6
clinical features, 724
diagnosis, 725
treatment, 725–6
prognostic factors, 729
recurrent disease, 733
staging, 727–9
- vulvar conditions, *see also* vulvar
infections; *specific
conditions*
cancers, 723, *see also* vulvar
carcinoma; vulvar
melanoma
characterization by
appearance, 275
classification, 268
dermatoses, 269
diagnosis, 269
history, 268–71
elderly patients, 46
lichen sclerosis, 542–3
non-invasive epithelial
disorders, 269, 272–8
pediatric patients, 540–5
physical examination, 268–9
associated signs, 269
lesion characteristics,
268–9
prevalence, 268
treatments, 269–70
immune modulators, 270
oral antihistamines, 270
topical steroids, 269–70
ulcers, 543–4
- vulvar hematomas, 563–4
treatment, 567–8
- vulvar infections, 270–1, 307
candidiasis, 270, 312–13
diagnosis, 313–14
management, 314–15
- risk factors, 314
- carbuncles, 309
- erysipelas, 308
- folliculitis, 308–9
- furuncles, 309
- hidradenitis suppurativa,
309–10
- HPV, 270
- necrotizing fasciitis, 315–16
management, 316
- pediatric patients, 540–52
causes, 552
management, 542
- pyoderma, 308
- soft tissue infections, 308
- vulvar intraepithelial neoplasia
(VIN), 269, 378
HIV association, 366
- vulvar lacerations, 564
treatment, 568
- vulvar melanoma, 46, 733–4
- vulvar vestibulitis, 57, 279
- vulvodynia, 278–9
localized, 57
treatment, 279
- warts, *see* genital warts
- weight loss, PCOS management,
1035–7, *see also* obesity
- Wharton–Sheares–George
neovagina creation
technique, 583
- white blood cell count, pelvic
inflammatory disease,
353
- wild yam, 90
- wrist fracture, 4
- Young syndrome, 903
- Z-score, 6